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ABSTRACT 
Isoflavonoids are phytoestrogens present in soybeans concomitantly with soy protein, and 
they resemble estradiol in structure and manner of action. Isoflavones such as genistein and 
daidzein bind weakly to estrogen receptor ? and more strongly to estrogen receptor ?, and as 
this binding is tissue-specific, they possess organ-specific estrogenic and antiestrogenic 
effects. A high intake of dietary phytoestrogens has been suggested to account for the lower 
rates of climacteric complaints, cardiovascular diseases, breast and endometrial cancers, and 
osteoporosis-related fractures in Asian than in Western countries. We examined the effects of 
isolated isoflavones on menopausal symptoms, quality of life, working capacity, vaginal and 
endometrial epithelium, and markers of bone and vascular health in symptomatic 
postmenopausal women with a history of breast cancer in a randomized placebo-controlled 
crossover trial involving 64 women, who used both phytoestrogen (114 mg isoflavonoids/day) 
and placebo for 3 months. Fifty-six women completed the 8-month study.  
The phytoestrogen regimen raised the circulating levels of isoflavonoids 
(daidzein, genistein, equol) 19- to 100-fold, but it failed to improve climacteric symptoms. 
The parameters reflecting quality of life such as working capacity and mood changes were 
unaffected by phytoestrogen. In addition, isoflavonoids caused no changes in circulating 
concentrations of follicle-stimulating hormone, luteinizing hormone, estradiol, or sex 
hormone-binding globulin. Twenty-five of 56 women (44.6%) preferred the phytoestrogen 
regimen as compared with 15 (26.8%) who preferred the placebo (p > 0.05), and 16 (28.6%) 
reported no preference. 
Isoflavonoids did not relieve vaginal dryness nor did they improve the 
maturation index of vaginal epithelium. Moreover, they caused no changes in endometrial 
thickness, histology, and expression of estrogen and progesterone receptors and the 
proliferation marker Ki-67.  
Markers of bone resorption (deoxypyridinoline, pyridinoline and N-terminal 
cross-linked telopeptide of type I collagen) were reduced during isoflavonoid use, compared 
with the placebo. The fall in deoxypyridinoline was significant (5%; p = 0.022) and the falls 
in levels of pyridinoline (9%; p = 0.084) and N-terminal cross-linked telopeptide of type I 
collagen (7%; p = 0.082) showed a trend towards significance. These changes may imply a 
mild useful effect of isoflavonoids on bone, although bone formation markers (bone-specific 
alkaline phosphatase and amino-(N-)terminal and carboxy-(C-)terminal procollagen type I) 
were not affected by isoflavonoids. 
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Isoflavonoids did not affect the concentrations of lipids or lipoproteins (total 
cholesterol, high- and low-density lipoprotein cholesterol, triglycerides, apolipoproteins B and 
A1, and lipoprotein (a)), or insulin sensitivity, as assessed by an oral 2-h glucose tolerance 
test (75 g). Changes in the levels of ghrelin were significantly different during the 
isoflavonoid (-7.1 ? 151 µmol/L) and placebo regimens (+47.9 ? 198 µmol/L) (p = 0.048). 
The levels of C-reactive protein and nitrate were not affected by isoflavonoids, but the levels 
of E-selectin were reduced by 4.0% (= 2.9 ng/mL) (p = 0.031) during isoflavonoid use; 
however no difference in these three markers between the study groups was seen at three 
months. These neutral effects on vascular surrogate markers fail to support a vasoprotective 
role of isoflavonoids. 
In conclusion, pure isoflavonoids (114 mg for three months) did not have 
estrogen-like effects in postmenopausal women, except for mild inhibition of bone resorption. 
Thus, their use for the treatment of menopausal symptoms cannot be supported by our data.  
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INTRODUCTION
Postmenopausal complaints, such as hot flashes, sleep disturbances and atrophic urogenital 
symptoms, are most effectively treated by hormone therapy (HT) (MacLennan et al. 2001,
Stearns et al. 2002). Observational studies have indicated that HT also reduces the risk of 
osteoporotic fractures and cardiovascular disease (CVD) (Weiss et al. 1980, Colditz et al. 
1987, Kiel et al. 1987, Cauley et al. 1995, Grodstein et al. 2000) and, accordingly, HT has 
been recommended not only for treatment of incapacitating climacteric complaints, but also 
for the prevention of chronic diseases such as osteoporosis and CVD (Grady et al. 1992). 
However, a number of recent randomized placebo-controlled trials have shown no benefit of 
HT in primary or secondary prevention of CVD (Hulley et al. 1998, Herrington et al. 2000,
Grady et al. 2002, Rossouw et al. 2002, Waters et al. 2002, Hodis et al. 2003, Manson et al.
2003, The Women’s Health Initiative Steering Committee 2004). These data, combined with 
the well established increased risk of breast cancer in HT users (Collaborative Group on 
Hormonal Factors in Breast Cancer 1997, Rossouw et al. 2002, Million Women Study 
Collaborators 2003) have cast doubts on the wisdom of using HT for prevention of chronic 
diseases and, therefore, HT is currently recommended primarily for treatment of climacteric 
complaints (Grady 2003, Grodstein et al. 2003, Manson et al. 2003), even though it also 
reduces the risks of fractures and colon cancer (Komulainen et al. 1998, Rossouw et al. 2002,
Chlebowski et al. 2004). 
The alarming reports briefly mentioned above have intensified a search for 
effective alternatives for treatment of climacteric complaints. Phytoestrogens are plant 
compounds that resemble estrogen in structure and function (Knight and Eden 1996). As they 
bind weakly to estrogen ?-receptor and more strongly to estrogen ?-receptor, they compete 
with estradiol at the same receptor sites and may exert organ-specific estrogenic or 
antiestrogenic effects by blocking the estrogen receptor and possessing weak estrogenic 
activity (Kuiper et al. 1998, Murkies et al. 1998). High consumption of phytoestrogens in 
Asian countries has been suggested to account for the low risk of CVD, breast and 
endometrial cancers, and osteoporosis-related fractures in these countries (Adlercreutz 1990, 
Ho et al. 1993, Murkies et al. 1998, Tham et al. 1998, Albertazzi and Purdie 2002). 
Furthermore, in Asia, where soy, a major source of phytoestrogens, is consumed 10–20 times 
more than in Western countries (Adlercreutz et al. 1992, Tham et al. 1998), only a minority of 
postmenopausal women report hot flashes (Boulet et al. 1994, Ho et al. 1999). The reason for 
the lack of vasomotor symptoms may be found in the high intake of phytoestrogens in food, 
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although differences in race, culture, climate, and even in language, finding no suitable words 
for reporting hot flashes, may be possible explanations. Therefore, phytoestrogens have been 
thought to hold a promise as an alternative therapy for menopausal symptoms, and they have 
been widely used, even though scientific evidence of their efficacy is poor or totally lacking 
(Kaufert et al. 1998, Davis 2001, Kam et al. 2002, Naftolin and Stanbury 2002). Hence, we 
designed a randomized placebo-controlled study to evaluate the usefulness of phytoestrogens 
in the treatment of menopausal complaints and the effects of isoflavonoids on surrogate 
markers of bone and vascular health.  
    13
REVIEW OF THE LITERATURE 
1. MENOPAUSE
Menopause, the cessation of natural menstruation, occurs on average at the age of 51 years 
(range 45–55 years) all over the world (McKinlay et al. 1992, Oldenhave et al. 1993, Boulet 
et al. 1994). Menopausal age has not shown any changes for many decades, although the life 
expectancy of women in developed countries has consistently increased and is now 82 years 
in Finland (www.stat.fi). This means that a woman today has one third of her life ahead when 
she enters menopause (Manson and Martin 2001). At menopause the circulating levels of 
estradiol decline extensively owing to depletion of ovarian follicles (Gruber et al. 2002). 
Because of estrogen’s lacking negative feedback on the hypothalamus and hypophysis, the 
fall of estradiol results in increased secretion of follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) (Robertson and Burger 2002). The fall of inhibin secreted from the 
ovary coincides with these changes (Robertson and Burger 2002). Although these changes are 
a part of natural physiology, they are associated with a number of estrogen –deficiency-
related symptoms (Table 1) (Stadberg et al. 1996, Dennerstein et al. 2000, Stearns et al. 
2002).
Table 1. The frequency (%) of the most common climacteric symptoms 
Frequency (%) 
Hot flashes 41–80 
Night sweats or chills 24–42 
Sleeping problems (insomnia, waking) 38–50 
Increased irritability, difficulty in concentrating 20–70 
Melancholy or depressive mood 25–57 
Loss of energy 38–42 
Muscle and joint pain 45–57 
Headache 32–42 
Palpitations 10–40 
Vaginal dryness 25–47 
Loss of libido 20–40 
Urinary incontinence and infections 15–25 
Formication 20–30 
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1.1 Immediate climacteric symptoms 
Various vasomotor symptoms, such as hot flashes, sweating, and palpitations, are present in 
60–80% of Western women entering menopause (Stearns et al. 2002, North American 
Menopause Society 2004). They usually last for two years, but may persist for up to 15 years 
in 20% of women (Stearns et al. 2002). Vasomotor symptoms appear to be more common and 
severe in women whose menopause follows oophorectomy (Bachmann 1999, Taylor 2001).  
The frequency and severity of hot flashes vary between different populations 
and cultures (Boulet et al. 1994, Ho et al. 1999, North American Menopause Society 2004). 
They are characterized by sensations of heat associated with a local cutaneous vasodilatory 
reaction and a subsequent drop in body temperature. The pathophysiology of hot flashes is 
poorly known, but they appear to arise as a result of an alteration in the hypothalamic 
thermoregulatory center, which is triggered by a reduction in circulating estrogen levels 
(Bachmann 1999). Estrogen deficiency can also result in central noradrenergenic 
hyperactivity and in a decrease in brain serotonin, which may contribute to vasomotor 
symptoms (Stearns et al. 2002).
Hot flashes are often accompanied by sweating, flushing, palpitations, anxiety, 
irritability, and panic disorders (Kronenberg 1994). They are more common in smokers and/or 
underweight women, and in women who exercise little (Stearns et al. 2002). Aside from hot 
flashes, the menopause is also accompanied by depressive moods, insomnia, and inability to 
concentrate (Stearns et al. 2002). These annoyances can be primary consequences of 
menopause, but, as is often thought, they can be secondary to vasomotor symptoms. 
Postmenopausal symptoms as a whole can be assessed more objectively with the aid of 
various indices, of which the Kupperman index has been used for the longest time 
(Kupperman et al. 1959).
1.2 Urogenital symptoms 
In view of the presence of estrogen receptors (ERs) in urogenital epithelia (Kuiper et al. 
1998), it is understandable that estrogen deficiency can be accompanied by urogenital 
atrophic symptoms, which usually begin few years after the menopause (Cardozo et al. 1998). 
They are complained of by 10–40% of postmenopausal women. The most common 
complaints are vaginal discharge, itching, burning, dyspareunia, and recurrent urinary and 
vaginal infections (Raz and Stamm 1993, Barlow et al. 1997, Cardozo et al. 1998).
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Approximately 10 to 15% of women over 60 years of age report recurrent urinary tract 
infections (Raz and Stamm 1993).
1.3 Bone loss 
Bone mass is maximal in women at the age of 20 to 30 years (Kanis 2002). Thereafter, 
skeletal mass and bone density remain relatively constant until the menopause, when bone 
loss is accelerated because of estrogen deficiency (Kanis 2002). This is a result of both 
activated bone resorption (osteoclast effect), and reduced bone formation (osteoblast effect) 
(Seeman 2002). Both osteoclasts and osteoblasts express estrogen receptors and are direct 
targets for estrogen (Gruber et al. 2002). Because of estrogen depletion women lose 
approximately 2% of their bone mass per year in the first 4–5 postmenopausal years and 
approximately 1% per year thereafter (Kanis et al. 1994, Seeman 2002). In lumbar spine, 
bone loss continues longer than in the femoral neck (Sirola et al. 2003). Increased bone loss 
may result in osteoporosis, which is defined by the World Health Organization as bone 
mineral density (BMD) in lumbar spine and/or femoral neck more than 2.5 SDs below the 
mean peak value in young adults (Melton 1995).  
Various biochemical markers reflecting bone resorption (N-terminal cross-
linked telopeptide of type I collagen (NTx), pyridinoline (Pyr), and deoxypyridinoline 
(Dpyr)), and formation (bone-specific alkaline phosphatase (BAP) and amino- (N-) terminal 
and carboxy- (C-) terminal procollagen type I (PINP and PICP, respectively)) can be used for 
assessing accelerated bone turnover and predicting fractures and monitoring the efficacy of 
osteoporosis treatment (Delmas 2000, Sarkar et al. 2004). Osteoporosis itself hardly causes 
any symptoms but it is a marker of increased risk of bone fractures; they are some 5–10 times 
more common in osteoporotic than in non-osteoporotic women (Kanis 2002).
Postmenopausal women have a 15–17% lifetime probability of either a hip or a 
vertebral fracture (Melton 2000). Both fractures are associated with increased mortality and 
they can often permanently diminish the quality of life (Cummings and Melton 2002). Thus, 
the prevention of osteoporosis and osteoporosis-related fractures is an important health issue 
in all developed countries.
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1.4 Cardiovascular disorders 
Cardiovascular diseases are five times more infrequent in premenopausal women than in age-
matched men (Barret-Connor and Bush 1991, Isles et al. 1992). Premenopausal women seem 
to tolerate classical CVD risk factors such as smoking, high levels of cholesterol, 
hypertension, and overweight better than men do (Barret-Connor 2003). Likewise, stroke and 
other forms of occlusive vascular disorders affecting the central nervous system are more 
infrequent in women in fertile age groups than in men (Barrett-Connor 1997). However, after 
the onset of menopause the occurrence of CVD abruptly rises and by the age of 70 years it is 
equal in women and men (Carr 2003). In addition, women who undergo surgical menopause 
or experience premature ovarian failure are characterized by a two-fold risk of coronary artery 
disease versus women entering menopause at 50 years of age, if the estrogen deficiency is not 
treated (Colditz et al. 1987, Barret-Connor and Bush 1991, van der Schouw et al. 1996). All 
this has been seen as evidence that estrogens protect women from CVD (Barret-Connor 
2003).
A number of pieces of information support the beneficial effects of estrogen on 
the vascular system (Table 2). Estrogen deficiency appearing at menopause is accompanied 
by rises (6–11%) in the levels of total and low-density lipoprotein (LDL) cholesterol, and 
triglycerides, and with a fall (7%) in high-density lipoprotein (HDL) cholesterol (Gaspard et
al. 1995). Moreover, weight, amount of abdominal fat, and insulin resistance increase after 
the onset of menopause. These phenomena may all contribute to an elevated risk of CVD 
(Stevenson et al. 1993, Gaspard et al. 1995, Sites et al. 2002, Greenland et al. 2003). Insulin 
resistance syndrome includes in addition to decreased insulin sensitivity abnormalities in the 
concentrations of lipids and lipoproteins, hypertension, and often abdominal obesity (Reaven 
et al. 1996, Ukkola 2003). Ghrelin, which is synthesized in an empty stomach and induces 
hunger (Kojima et al. 1999, Schöfl et al. 2002, Ukkola 2003), is produced in response to 
insulin-induced hypoglycemia (Toshinai et al. 2003). Because fasting plasma levels of ghrelin 
are negatively correlated with the amount of body fat and fasting levels of insulin (Ukkola 
2003), ghrelin may appear to improve insulin sensitivity.  
Atherosclerotic diseases in the coronary and other arteries can be a reflection of 
inflammation, which induces C-reactive protein (CRP) production in the liver (Ross 1999). 
Thus, high levels of CRP may predict an increased risk of CVD (Ridker et al. 1998, Lagrand
et al. 1999, Visser et al. 1999, Ridker et al. 2000, Danesh et al. 2004). E-selectin and nitric 
oxide (NO) are produced in endothelial cells. E-selectin facilitates the recruitment of 
leukocytes from the blood stream to activated endothelium (Gearing and Newman 1993, 
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Malik et al. 2001, Ylikorkala et al. 2003) and may play a role in the development of 
atherosclerosis (Farzati et al. 2002). Nitric oxide induces vasodilatation, and suppresses 
platelet aggregation and adhesion, the development of atherosclerotic plaques, and vascular 
smooth muscle proliferation, hence protecting from CVD (Majmudar et al. 2000). Thus, in 
principle, a “low” level of E-selectin and a “high” level of NO in vascular endothelium should 
be protective against vascular disorders. It is known that at menopause the levels of E-selectin 
increase (Kennedy et al. 1999) and NO activity is reduced, measured as a vasodilatory 
response to intra-arterial infusion of acetylcholine (Majmudar et al. 2000), supporting a 
possible role of these agents in menopause-related vascular disorders.
Table 2. Effects of estrogen on some factors associated with cardiovascular diseases 
Oral estrogen Transdermal estrogen 
Total cholesterol ?? ?
Low-density lipoprotein 
(LDL) cholesterol  ?? ?
High-density lipoprotein 
(HDL) cholesterol ?? ?
Triglycerides ? ?,?
Lipoprotein (a)  ? ?
Insulin sensitivity ? (?)




- C-reactive protein 


















Homocysteine ?,?, ? ?,?
2. HORMONE THERAPY
This thesis focuses on the possibility of treating menopausal symptoms with phytoestrogens 
and therefore, conventional hormone (replacement) therapy is dealt with here only as regards 
the main principles. Menopausal complaints have been treated with estrogen, alone or 
together with progestin, for more than 50 years (Barret-Connor 2003). Estrogen can be given 
orally, transdermally, intranasally or subcutaneously, and progestin orally, transdermally, or 
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via an intrauterine route (North American Menopause Society 2004). Hormone replacement 
therapy (HRT), nowadays called hormone therapy (HT) especially in the USA, is considered 
to be the most effective, although not a harmless treatment for climacteric complaints 
(MacLennan et al. 2001, Stearns et al. 2002) (Table 3). However, only 35–40% of 
postmenopausal women of 50 to 74 years of age in the USA use HT, and approximately 50–
60% discontinue it in less than a year (Keating et al. 1999, Ettinger et al. 1999a). Only 20% 
of all postmenopausal women use HT for 5 years or more (Brett and Madans 1997). In 
Finland, 22% of all postmenopausal women used HT in 2002, the total number of users being 
340 000 (Salmi et al. 2004). Use of HT was most common among women of 55–56 years of 
age, and 43% of them used systemic HT (Salmi et al. 2004).
Only estrogen is needed for alleviating menopausal complaints, but because of 
an increased risk of endometrial cancer, unopposed estrogen can be safely used only in 
hysterectomized women. In women with an intact uterus estrogen is administered with 
progestin, which modifies the response to HT differently in various organs (North American 
Menopause Society 2004).
Table 3. Confirmed and disputable benefits and harm of hormone therapy 
Placebo-controlled evidence of benefits
Hot flashes and other immediate climacteric symptoms decrease/disappear 
Improvement of quality of life in symptomatic women 
Strengthening of vaginal and urogenital epithelium 
Prevention of bone loss and fractures 
Protection against colon cancer 
Disputable evidence of benefits/harm
Protection against cardiovascular diseases 
Protection against deterioration in cognitive function and/or Alzheimer’s disease  
Placebo-controlled evidence of harm
Breast cancer 




2.1 Benefits – confirmed and disputable 
Hormone therapy alleviates the frequency and severity of hot flashes by 50–100% within a 
few days after its initiation (McNagny 1999, MacLennan et al. 2001). This results in 
improvement of quality of life in women with hot flashes whereas this effect is disputable in 
women without vasomotor symptoms (Barrett-Connor 1998). Estrogens also strengthen the 
vaginal epithelium effectively whether given systemically (Nilsson et al. 1995, Vardy et al. 
2003) or intravaginally (Cardozo et al. 1998, Šimuni? et al. 2003).
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Estrogen suppresses bone loss by inhibition of bone resorption, resulting in a 5–
10% increase in BMD over 1–3 years (Delmas 2002, Eviö et al. 2004). There is substantial 
epidemiological evidence that estrogen/hormone therapy (ET/HT) also protects against bone 
fractures (Lindsay 1993, Komulainen et al. 1998, Torgerson and Bell-Syer 2001, Wells et al. 
2002). In observational studies ET has reduced vertebral fractures by approximately 50% and 
hip fractures by 25 to 30% (Barrett-Connor 1998). Furthermore, in the randomized, placebo-
controlled Women’s Health Initiative Study (the WHI Study) hip fractures were reduced by 
33% with HT-use (Cauley et al. 2003). The absolute risk reductions per 10 000 person-years 
were 5 fewer hip, 18 fewer wrist/lower arm and 47 fewer total fractures (Cauley et al. 2003). 
Colon cancer is second to breast cancer in the incidence of all cancers in Finnish 
women (www.cancerregistry.fi); 743 women were diagnosed with colon cancer in 2001 
(www.cancerregistry.fi). Many observational studies have shown a reduction in the 
occurrence of colon cancer in HT users (Manson and Martin 2001). This protective effect was 
not seen in the Heart and Estrogen/progestin Replacement Study (HERS) (Hulley et al. 1998),
whereas in the WHI Study HT was associated with 6 fewer colorectal cancers per 10 000 
women-years after a mean of 5.2 years (Rossouw et al. 2002), however, colorectal cancers in 
women who took estrogen plus progestin were diagnosed at a more advanced stage than those 
in women who took placebo (Chlebowski et al. 2004). In a meta-analysis of 27 studies, HT 
reduced the risk of colon cancer by 30% (Nanda et al. 1999). It has been shown that estrogen 
receptors are expressed in normal colonic epithelium, but they become largely suppressed in 
colonic cancer tissue (Al-Azzawi and Wahab 2002). An inhibitory effect of estrogen on 
colonic cancer cellular proliferation in in vitro studies has also been documented, but the 
detailed mechanism by which estrogen protects against colon cancer is still unknown (Al-
Azzawi and Wahab 2002). 
2.2 Risks – confirmed and disputable 
Breast cancer 
In a reanalysis of 51 epidemiological studies on 52 705 breast cancer patients and 108 411 
controls, the relative risk (RR) of breast cancer was increased in current users of HT by a 
factor of 1.023 for each year (Collaborative Group on Hormonal Factors in Breast Cancer 
1997). The risk vanished within 5 years after cessation of HT, but the cumulative excess 
numbers of breast cancers diagnosed between the ages of 50 and 70 per 1000 women using 
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HT for 5, 10 and 15 years were estimated to be 2, 6 and 12, respectively (Collaborative Group 
on Hormonal Factors in Breast Cancer 1997).  
In the Million Women Study, British women between  50 and  64 years of age 
(n = 1 084 110 women screened; 829 000 completed the study) reported their use of HT at the 
time of routine screening mammography, which was done every 3 years (Million Women 
Study Collaborators 2003). The relative risk of breast cancer in current users of HT was 1.66. 
The type of estrogen and the mode of administration did not affect the incidence of breast 
cancer, whereas the adjusted RR was significantly greater for estrogen-progestin therapy 
(EPT) (2.00) than for ET (1.30) or tibolone (1.45) (Million Women Study Collaborators 
2003). In a similar cohort study carried out in Finland in 1987–1995 no increase in the 
incidence of breast cancer during ET was found (Sourander et al. 1998).
In the WHI Study the absolute excess risk per 10 000 person-years in the EPT 
group was eight more cases of invasive breast cancers (Rossouw et al. 2002, Chlebowski et
al. 2003). The breast cancers were similar in histology and grade, but were more likely to be 
diagnosed at a more advanced stage during HT –use, suggesting that estrogen plus progestin 
may stimulate breast cancer growth and hinder breast cancer diagnosis (Chlebowski et al. 
2003). In the estrogen-only arm no breast cancer risk was found after 7 years’ use of estrogen, 
in fact 7 fewer cases of breast cancer per 10 000 person-years were diagnosed during estrogen 
use when compared with placebo (The Women’s Health Initiative Steering Committee 2004). 
Endometrial cancer 
Several observational studies have demonstrated that unopposed use of estrogen is associated 
with an increased risk of endometrial cancer (Grady et al. 1995). However, addition of 
progestin, opposing the effect of estrogen on the endometrium eliminates the risk (Manson 
and Martin 2001).
Thromboembolism 
An increased risk of venous thromboembolism (VTE) in users of HT is well established. The 
absolute excess risk per 10 000 person-years in observational studies has been two more cases 
of VTE, and 18–39 more cases with HT –use in randomized studies, the excess risk being 
highest during the first year after initiation of HT (Daly et al. 1996, Grady et al. 2000,
Manson and Martin 2001, Rossouw et al. 2002).
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Stroke
In the observational Nurses’ Health study of 70 533 postmenopausal women, 767 strokes 
were diagnosed, the risk of stroke being statistically increased among women taking 0.625 mg 
or more of conjugated estrogen daily (RR 1.35 for estrogen only and 1.63 for estrogen plus 
progestin), whereas in women taking 0.3 mg of conjugated estrogen it was decreased (RR 
0.58) (Grodstein et al. 2000). An increased risk of stroke was also found in the WHI study, 
where EPT was associated with eight and ET with twelve more cases of stroke per 10 000 
person-years (Rossouw et al. 2002, The Women’s Health Initiative Steering Committee 
2004).
Cognitive function 
Results on the effects of HT on cognitive function have been controversial. In two meta-
analyses of estrogen and dementia, risk reductions of 29% (Yaffe et al. 1998) and 34% 
(Nelson et al. 2002) were reported, but in the randomized WHI Memory Study (WHIMS) 
continuous-combined estrogen plus progestin did not improve cognitive function and was 
even associated with an increased risk of probable dementia (Rapp et al. 2003, Shumaker et 
al. 2003). WHIMS can be criticized, however, on the basis of subject selection – only women 
older than 65 were included. It has been suggested that HT is most beneficial at menopause, 
when the abrupt depletion of endogenous estrogen may have the greatest deleterious effect on 
neurons (Zandi et al. 2002). Furthermore, there appears to be a limited window of time during 
which HT exposure seems to reduce the risk of impairment of cognitive function (Zandi et al. 
2002). Thus the results of WHIMS cannot be expanded to concern women who have only just 
reached their menopause.   
Cardiovascular disease 
In observational studies the risk of major coronary events in women without previous heart 
disease was 40% lower among current users of HT compared with never-users (Grodstein et
al. 2000). A similar risk reduction (RR 0.65) has also been seen with long-term HT –use in 
women with previous myocardial infarction, although HT –use for less than a year increased 
the risk of a recurrent major coronary event (RR 1.25) (Grodstein et al. 2001). In a Finnish 
cohort study, current ET was associated with decreased cardiovascular mortality (RR 0.21 in 
current users of ET) and a decrease in sudden cardiac death, although there was no change in 
cardiovascular morbidity (Sourander et al. 1998). However, observational studies have been 
criticized on the basis of healthy user and compliance bias; women taking estrogens may have 
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better levels of several heart disease risk factors (Garbe and Suissa 2004) and persons who 
comply with even placebo use have substantially lower rates of heart disease (Grodstein et al.
2003).
The suggested mechanisms for explaining CVD protection have been beneficial 
changes in lipids and lipoproteins (The Writing Group for the PEPI Trial 1995, Godsland 
2001), 18–35% decreased circulating levels of E-selectin (Cushman et al. 1999, Vehkavaara 
et al. 2001, Farzati et al. 2002, Ylikorkala et al. 2003) and stimulated NO production induced 
by HT (Rosselli et al. 1995, Imthurn et al. 1997, Davison and Davis 2003). However, in 
recent randomized trials no cardiovascular benefit, or even adverse effects with HT have been 
reported (Hulley et al. 1998, Herrington et al. 2000, Grady et al. 2002, Rossouw et al. 2002, 
Waters et al. 2002, Hodis et al. 2003, Manson et al. 2003, The Women’s Health Initiative 
Steering Committee 2004).
The placebo-controlled WHI reported seven more cardiac events/10 000 
woman-years for users of conjugated estrogens + medroxyprogesterone acetate (Rossouw et
al. 2002, Manson et al. 2003). However, the WHI has been strongly criticized for many 
reasons. First of all, the women did not represent healthy postmenopausal women seeking 
help for hot flashes, e.g. the women did not report climacteric symptoms, they were on 
average 63 years of age, and 36% received medication for hypertension and 13% for elevated 
cholesterol levels. Second, in the WHI, HT was initiated at a mean of 10 years after the 
menopause. As a woman’s age and the number of years since menopause are potential factors 
modifying the influence of hormones on CVD, it has been suggested that HT could be 
beneficial in women who start HT before they have developed arteriosclerotic plaques 
(Grodstein et al. 2003). It has also been suggested that in the WHI a detection bias related to 
differential unblinding of HT users could have resulted in higher detection rates of otherwise 
unrecognized acute myocardial infarction, hence affecting the results (Garbe and Suissa 
2004). Thus, there remain unanswered questions in the field of prevention of CVD by HT. 
However, at the moment HT cannot be primarily recommended for primary or secondary 
prevention of CVD (Grodstein et al. 2003, Ylikorkala 2004). 
3. NON-ESTROGENIC HORMONAL ALTERNATIVES
Women with contraindications for conventional HT have used natural progesterone and 
synthetic progestins for the relief of hot flashes (Ylikorkala and Metsä-Heikkilä 2002, North 
American Menopause Society 2004). Progesterone, megesterol acetate and 
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medroxyprogesterone acetate orally, transdermally or intramuscularly have been associated 
with an 80–90% reduction in hot flashes (Loprinzi et al. 1994, Quella et al. 1998, Leonetti et
al. 1999, North American Menopause Society 2004). However, progestins have to be used 
with caution, as they might stimulate tumor growth in excess to that observed with estrogen 
(Ross et al. 2000, Million Women Study Collaborators 2003, Holmberg and Anderson 2004).  
Tibolone is a synthetic progestin that is metabolized to estrogenic, androgenic 
and progestogenic compounds. It can be used for relieving vasomotor symptoms and bone 
loss (Albertazzi et al. 1998). It reduces the levels of total cholesterol, LDL cholesterol and 
lipoprotein A-1, but it also reduces the levels of HDL cholesterol and triglycerides (Bjarnason 
et al. 1997). As yet, there are no randomized studies on its effects on breast cancer risk, but in 
the Million Women Study the incidence of breast cancer was comparable to that associated 
with current use of tibolone (RR 1.45) and estrogen-only (RR 1.30) (Million Women Study 
Collaborators 2003).
Selective estrogen-receptor modulators (SERMs), such as tamoxifen, 
toremifene, raloxifene, ospemifene, and bazedoxifene exert estrogen agonist or antagonist 
effects depending on the target tissue (Biskobing 2003, Riggs and Hartmann 2003). They 
have several beneficial estrogenic effects on bone (Marttunen et al. 1998, Ettinger et al. 
1999b), lipids and lipoproteins (Saarto et al. 1996, Walsh et al. 1998), and various 
vasoregulators (Walsh et al. 1998, Marttunen et al. 2000, Ylikorkala et al. 2003b), but an 
antiestrogenic effect on breast tissue (Early Breast Cancer Trialists’ Collaborative Group 
1998, Cummings et al. 1999). Raloxifene, the most established SERM and the only one 
approved by the U.S Food and Drug Administration (FDA) for treatment of osteoporosis, 
does not alleviate vasomotor symptoms and vaginal atrophy, but even worsens them (Vardy et
al. 2003). In this regard, newer SERMs such as ospemifene and bazedoxifene may hold 
promise (Biskobing 2003, Rutanen et al. 2003, Ylikorkala et al. 2003b). 
4. NON-HORMONAL ALTERNATIVES
There exist a variety of non-hormonal alternatives for treating menopausal complaints, 
including lifestyle modification such as keeping the body cool and exercising regularly (Table 
4). Many of the pharmacologic alternatives have been studied in breast cancer patients, who 
are usually not given HT (Colditz 1997, Consensus statement 1998). 
In a Swedish study, 41.4% of postmenopausal women had used HT at some 
time, while 45% had used a non-hormonal  regimen  (Stadberg et al. 1997).  Clonidine, an  
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?2-adrenergic receptor agonist, given either orally or transdermally, can alleviate hot flashes, 
but, because of adverse effects such as dry mouth, constipation and drowsiness in 10–50% of 
patients, it is no real alternative to HT (Goldberg et al. 1994, Pandya et al. 2000). Beta-
blockers such as propranolol can alleviate palpitations, but their ability to improve hot flashes 
is modest and therefore they are not recommended for treatment of menopausal complaints 
(Carranza-Lira and Cortés-Fuentes 2001). 
Antidopaminergic compounds, such as veralipride and methyldopa, may 
alleviate hot flashes, but because of a number of side effects they have no place in the 
treatment of menopausal symptoms (Vercellini et al. 1992). 
A combination of ergotamine, belladonna alkaloids and phenobarbital has been 
used for relieving climacteric symptoms for many years, although data on its efficacy are 
controversial or totally lacking (Gass and Taylor 2001). The product is no longer 
manufactured and can be purchased only when specially made in the pharmacy. 
Of selective serotonin reuptake inhibitors (SSRIs), fluoxetine and venlafaxine 
have been shown to reduce hot flashes in placebo-controlled randomized studies (Loprinzi et
al. 2000, Loprinzi et al. 2002). They are often recommended for patients with severe 
symptoms and contraindications for HT (Anderson 2000), but in clinical practice many 
women are reluctant to start using a psychotropic drug. In addition, SSRIs have moderate side 
effects, such as dry mouth, nausea, decreased appetite, constipation, sleeping difficulties, and 
withdrawal symptoms (Anderson 2000). Moreover, no long-term data exist on their final 
efficacy and safety. Hence they seldom are a real alternative to HT in clinical practice.   
Vitamin E has been recommended for treating hot flashes, although its efficacy 
is poorly confirmed. In a randomized placebo-controlled crossover study of 125 breast cancer 
survivors, vitamin E (400 IU twice daily for 4 weeks) was associated with one hot flash less 
daily, which was statistically but not clinically significant (Barton et al. 1998).
Herbs used for menopausal problems include black cohosh, chaste tree berry, 
dong quai, ginseng, evening primrose oil, motherwort and licorice (Kronenberg and Fugh-
Berman 2002). They are most often sold and used under the assumption that “natural” 
products are “good” for your health and cause no harm, although hardly any real research data 
exist on their efficacy and safety. Black cohosh is probably the most popular herb, and 40 mg 
of this herbal drug/day for 3 months has been shown to be equipotent to 0.6 mg of conjugated 
estrogens in relieving climacteric complaints and affecting bone metabolism without 
stimulating the endometrium (Wuttke et al. 2003). However, no long-term data exist on black 
cohosh’s efficacy and adverse events.  
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Table 4. Non-hormonal alternatives for treating postmenopausal symptoms 
Alpha2-adrenergic -receptor-agonists:   Clonidine 
Beta-blockers:     Propranolol 
Antidopaminergic compounds:    Veralipride 
Methyldopa 
Ergotamine + belladonna alkaloids + phenobarbital 




Herbs:     Black cohosh 
Chaste tree berry 
Dong quai 
Ginseng 
Evening primrose oil 
Motherwort 
Licorice
5. BIOLOGY OF PHYTOESTROGENS
It has been known for almost one century that some plant extracts exhibit estrogenic activities 
(Murkies et al. 1998). The evidence was often anecdotal, but, for example, in the 1940s it was 
shown that sheep consuming high amounts of red clover became infertile because of the high 
intake of phytoestrogens (Murkies et al. 1998). Research on phytoestrogens was greatly 
stimulated when it became possible to assess their concentrations in urine in the 1980s 
(Setchell 2001), and later on, they were also identified and measured in bile, blood, feces, 
semen, breast milk and saliva (Murkies et al. 1998, Tham et al. 1998).
Table 5. Classification and sources of phytoestrogens. The precursors and biologically active components are 
also indicated 
Isoflavones Lignans Coumestans
Leguminous plants (soybean, lentils, 
beans, clover) 
Flaxseeds, grains, cereals, fruits 
(guava), berries (lingonberry, 
bramble), vegetables (broccoli) 
Bean sprouts, fodder crops 
Coumesterol 
Biochanin A 








5.1 Structure and classification  
The three main classes of phytoestrogens – isoflavones, lignans, and coumestans all occur in 
either plants and/or their seeds (Table 5). They possess estrogen-like structure (Murkies et al. 
1998, Albertazzi and Purdie 2002) but they are not steroids. However, owing to the presence 
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of phenolic rings in their molecules, they have the ability to bind to estrogen receptors 
(Setchell 1998) (Figure 1).
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5.2 Consumption and sources 
The consumption of phytoestrogens varies around the world; in Japan, Taiwan and Korea, 
where various products made of soy are a typical part of the everyday diet, people are 
estimated to consume 20–80 mg of isoflavones per day (Tham 1998, Somekawa 2001), 
whereas the dietary intake of isoflavones in Europe and USA has been estimated to be 0.5–3 
mg/day (Tham et al. 1998). Urinary excretion of isoflavonoids is 10–100 times higher in 
women consuming a traditional Japanese diet than in women consuming American or Finnish 
food (Adlercreutz et al. 1992).
Isoflavones occur in various fruits and vegetables, but especially in leguminous 
plants such as soybeans, clover and mung beans (Mazur 1998). The major isoflavones are 
genistein and daidzein, which are formed from their plant precursors, biochanin A and 
formononetin, respectively (Tham 1998). Lignans occur mostly in flaxseeds, cereals, fruits 
and berries and the major mammalian lignans, enterolactone and enterodiol, are the products 
of colonic bacterial metabolism of the plant lignans matairesinol and secoisolariciresinol 
(Lampe et al. 1994, Knight and Eden 1996) (Table 5).
The major dietary source of phytoestrogens in most populations is soy (Mazur 
1998). Soy protein can be isolated from whole beans and may be consumed in various 
products such as tofu, miso, meat products and nutritional supplements (Lusas and Riaz 
1995). The concentration of isoflavones in most soy food products ranges from 0.5 to 2 mg/g 
protein (Mazur 1998), although it may vary even more because of differences in crops, 
harvest years and processing techniques (Tham et al. 1998).
5.3 Absorption and metabolism 
Isoflavones are present in soy proteins and in most soy foods in conjugation with sugars 
(Setchell 2001). These glycosides are still inactive and must be first hydrolyzed to become 
biologically active (Setchell 2001). Hydrolysis occurs in the gastrointestinal tract, where 
bioactive aglycones, daidzein and genistein, are formed as a result of bacterial function 
(Setchell 2001). The aglycones may be absorbed into the circulation or further metabolized; 
daidzein to equol and 0-desmethylangolensin (0-DMA) and genistein to estrogenically 
inactive p-ethylphenol (Knight and Eden 1996, Setchell and Cassidy 1999). The metabolism 
of phytoestrogens in the gastrointestinal canal can be modified by changes in the gut bacterial 
flora, e.g. as a result of other components in the diet, antibiotic use, surgery, or bowel disease 
(Murkies et al. 1998). Thus, the fate of dietary-ingested phytoestrogens varies from one 
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person to another. There also appears to be a gender-dependent difference in metabolism; 
women metabolize diet-derived phytoestrogens more effectively to active compounds than 
men (Lu and Anderson 1998). The role of age and race in determining the ability to 
metabolize phytoestrogens is still unknown. 
After absorption, phytoestrogens, like estrogens, are prone to enterohepatic 
circulation (Setchell 2001). They are excreted in the bile, deconjugated by intestinal flora, 
reabsorbed, reconjugated by the liver, and excreted in the urine (Murkies et al. 1998, Setchell 
1998). Peak plasma concentrations of isoflavones are attained 5–6 hours after oral ingestion 
and the half-life of systemic elimination is in the range of 6–8 hours (Setchell 2001, Setchell 
et al. 2001). Urinary excretion of isoflavones rises with increasing intake of soy isoflavones, 
but only to a certain extent; the absorption capacity becomes saturated at high doses (Setchell 
et al. 2003). Furthermore, only 50–70% of adults excrete significant amounts of equol in the 
urine, even when consuming soy foods or even pure daidzein daily (Setchell et al. 2002). 
These “equol-producers” are individuals with an intestinal capacity to metabolize daidzein to 
equol (Setchell et al. 2002). Thus, it may be possible that soy protein diets are most beneficial 
in these subjects (Setchell et al. 2002).
5.4 Mechanism of action  
 Isoflavones, such as genistein and daidzein, bind weakly to ER? and more strongly to ER?
(Kuiper et al. 1998). Estrogen ?-receptors predominate in endometrium, ovarian stroma and 
breast cells, whereas estrogen ?-receptors predominate in bone, endothelium and brain 
(Kuiper et al. 1997, Gruber et al. 2002). Because of the different tissue distribution of ERs, 
isoflavonoids possess organ-specific estrogenic and antiestrogenic effects (Kuiper et al. 
1998). Thus, they fulfil the criteria of SERMs. The final effect of isoflavonoids seems to 
depend, in addition to receptor binding, on the circulating levels of phytoestrogens and 
endogenous estrogen, so that a “certain amount” of estrogen may appear mandatory for 
isoflavonoid action (Kuiper et al. 1997, Tham et al. 1998, Kuiper et al. 1998).
The relative abilities of different isoflavonoids to bind to ER? compared with 
estradiol (100) in in vitro studies have been as follows: genistein 4, daidzein 0.1, biochanin A 
< 0.01 and formononetin < 0.01 (Kuiper et al. 1998). Likewise, the abilities to bind to ER?
have been 87 for genistein, 0.5 for daidzein, and < 0.01 for both biochanin A and 
formononetin (Kuiper et al. 1998). The binding capacities of isoflavonoids to ER? and ER?
may not totally reflect their clinically significant effects, because they can be present in the 
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body at 100-fold higher concentrations than endogenous estrogens and they may also have 
direct nongenomic effects (Tham et al. 1998).
In animal studies and in vitro studies using breast cancer cell lines, isoflavones 
have induced tumor suppression (Setchell 1998). This phenomenon can be explained by 
several mechanisms. First, genistein may specifically inhibit tyrosine kinases (Akiyama et al.
1987) and DNA topoisomerases I and II (Okura et al. 1988, Markovits et al. 1989). Second, 
genistein also arrests cell growth by interfering with signal transduction pathways 
(Matsukawa et al. 1993). Third, isoflavonoids possess antioxidant (Wei et al. 1995),
antiproliferative (Yanagihara et al. 1993), anti-inflammatory (Wu et al. 1992), and 
antiangiogenetic properties (Fotsis et al. 1993), and they also inhibit the actions of cytokines 
and growth factors (Wilcox and Blumenthal 1995, Kim et al. 1998). Finally, isoflavonoids 
can inhibit cytokine-stimulated nitric oxide formation (Salzman et al. 1996) and aromatase 
activity (Adlercreutz et al. 1993), which may be of significance as regards tumor genesis. 
Thus, there exist several biologically plausible explanations for an anticancer effect of 
isoflavonoids, but clinical evidence of these benefits is still vague and awaits further 
evaluation.
6. CLINICAL EFFECTS OF PHYTOESTROGENS
As phytoestrogens resemble estrogen in structure, they are considered to have estrogen-like 
effects on various symptoms and organs (Albertazzi and Purdie 2002).
6.1 Climacteric symptoms
Data on the effects of soy or isolated isoflavones on climacteric complaints are controversial 
(Albertazzi and Purdie 2002). At the time of the design of our study there were only a few 
randomized studies, and even these trials were difficult to interpret, because many of them 
lacked a placebo group. In addition, follow-up was relatively short (6–12 weeks). Finally, the 
phytoestrogen compounds used in these studies varied from soy flour and tofu to red clover-
derived isoflavones (Table 6). Thus it was impossible to draw any concrete clinical 
recommendations.  
Possible estrogenic activity of phytoestrogens might be seen from estrogen-
controlled hormones. Most studies show that FSH and sex hormone-binding globulin (SHBG) 
are not affected by phytoestrogens (Baird et al. 1995, Murkies et al. 1995, Baber et al. 1999,
Knight et al. 1999, Scambia et al. 2000, Upmalis et al. 2000). However, the data are not 
uniform; SHBG concentrations were elevated with the use of 30 g soy milk daily for 10 
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weeks (Pino et al. 2000), with high isoflavone soy powder for 12 weeks (Duncan et al. 1999)
and with a phytoestrogen-rich diet for 12 weeks (Brzezinski et al. 1997). Phytoestrogens are 
not converted to estrogens, and therefore it was surprising to note that the level of estradiol 
rose and that of FSH declined during the use of isoflavones (100 mg/daily) for 4 months (Han 
et al. 2002). However, a similar decline in FSH levels was seen during the placebo regimen, 
which casts doubt on the specificity of the reported effects of isoflavonoids (Han et al. 2002).
Taken together, no firm conclusions could be made concerning the effects of isoflavonoids at 
the time of the start of our trial.  
Table 6. Randomized studies on the effects of phytoestrogens on hot flashes
Researchers Phytoestrogen 
Source, dose/day 
Study design Control N Results: Change 
of






Murkies et al. 
1995 
45 g soy flour Double-blind, 
12 weeks 
45 g wheat 
flour  
58 ? 40 – ? 25 NS 
Brzezinski et al.
1997 
80 g tofu, 400 ml soy 
drink, 1 ts miso, 2 ts 
flax seed  





145 ? 54 – ? 35 0.004 
Albertazzi et al.
1998 
60 g soy protein with  
76 mg isoflavones 
Double-blind, 
12 weeks  
60 g casein 104 ? 45 – ? 30 < 0.01 
Dalais et al. 1998 45 g soy or 45 linseed  Double-blind, 
crossover,  
12 weeks 
45 g wheat 
kibble  
52 ? 20  – ? 41  
– ? 51 
NS
Baber et al. 1999 Red clover derived 






51 ? 22 – ? 17 NS 
Knight et al.
1999 
Red clover derived 
isoflavonoids, 40mg 





37 ? 29 – ? 34 




20 g soy protein with 34 




20 g complex 
carbohydra-
tes
51 The exact change 
not reported. 
NS
N = number of women 
ts = teaspoon 
6.2 Vaginal epithelium and endometrium 
Vaginal epithelium and endometrium become atrophic a few years following the onset of 
menopause (Cardozo et al. 1998). Vaginal changes can be measured by cytological 
assessment of maturation of vaginal epithelium. Alleviation of subjective symptoms, such as 
dryness, may also indicate the effect of a given compound on the vagina. Neither soy with 
isoflavones (Albertazzi et al. 1999, Duncan et al. 1999) nor isolated isoflavones (40–50 
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mg/day) (Baber et al. 1999, Scambia et al. 2000, Upmalis et al. 2000) for 6–12 weeks have 
affected maturation indexes of vaginal epithelium. However, soy-supplemented diets 
containing isoflavones (53–165 mg/day) for 4–12 weeks (Baird et al. 1995, Dalais et al. 
1998), and soya flour (45 g/day) for two weeks (Wilcox et al. 1990) have been claimed to 
strengthen vaginal epithelium. In addition, some studies have indicated that soy isoflavones 
(100–118 mg/day) (Kotsopoulos et al. 2000, Han et al. 2002), or a phytoestrogen-rich diet for 
3–4 months (Brzezinski et al. 1997), could alleviate vaginal dryness. Thus, data on the effects 
of phytoestrogens on the vagina are far from being uniform. 
As regards the endometrium, phytoestrogens have had no effect on its thickness 
when given alone as isoflavones (40–72 mg/day) (Baber et al. 1999, Scambia et al. 2000,
Upmalis et al. 2000, Penotti et al. 2003) or in combination with soy protein for 3–6 months 
(Han et al. 2002). Neither have phytoestrogens had an estrogenic effect on endometrial 
histology (Duncan et al. 1999, Balk et al. 2002). Although ERs and progesterone receptors 
(PRs) are necessary for steroid hormone action and they are, at least partly, regulated by 
estrogen (Punuyadeera et al. 2003), no data exist on the effect of phytoestrogens on these 
receptors in human endometrium. Likewise, the expression of Ki-67 is often used as a marker 
of the proliferative effect of a given compound in the endometrium, but no data existed on the 
expression of Ki-67 during phytoestrogen use in postmenopausal women before our study. At 
present, there are no prospective data on the effects of phytoestrogens on the risk of 
endometrial cancer, although the results of three case-control studies suggest this risk could 
be reduced during the use of phytoestrogens (Goodman et al. 1997, Horn-Ross et al. 2003, Xu 
et al. 2004). Thus, solid scientific evidence of the effect of isoflavonoids on the vagina and 
endometrium was still awaited during the design of our study. 
6.3 Bone 
There are several mechanisms of action by which phytoestrogens may affect bone 
metabolism. First, osteoblasts abundantly express estrogen ?-receptors, which bind 
phytoestrogens. Thus the bone effect of phytoestrogens may closely resemble that of estrogen 
(Knight and Eden 1996, Kuiper et al. 1998). Other mechanisms of action include promotion 
of calcium absorption (Arjmandi et al. 2002) and increased production of insulin-like growth 
factor-1 (IGF-1) (Arjmandi et al. 2003), which is known to enhance osteoblastic activity and 
to correlate with bone formation (Arjmandi and Smith 2002, Arjmandi et al. 2003). Genistein 
without soy protein has also stimulated the production of osteoprotegerin by osteoblasts, 
which prevents bone resorption (Viereck et al. 2002). In early studies a synthetic 
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phytoestrogen called ipriflavone showed promise in preventing bone loss in postmenopausal 
women (Agnusdei et al. 1997, Gambacciani et al. 1997). However, this could not be 
confirmed in a randomized study, which also reported adverse reactions to ipriflavone such as 
lymphocytopenia (Alexandersen et al. 2001).
A high dietary intake (55 mg/day) and high urinary excretion of isoflavones are 
associated with high BMD in Chinese (Mei et al. 2001), Japanese (Somekawa et al. 2001) and 
Korean (Kim et al. 2002) postmenopausal female populations. However, data on the effects of 
isoflavonoid- or soy-rich diets on bone metabolism are inconsistent, showing a potential 
benefit in some (Potter et al. 1998, Alekel et al. 2000, Chiechi et al. 2002, Morabito et al. 
2002) but not in all studies (Wangen et al. 2000, Hsu et al. 2001, Dalais et al. 2003). Thus, 
more studies are needed to confirm the effects of phytoestrogens on bone. 
6.4 Markers of cardiovascular disease 
A high intake of dietary phytoestrogens has been suggested to account for the lower rates of 
CVD in Asia than in Western countries (Tikkanen and Adlercreutz 2000). This benefit has 
been thought to be mediated through favorable changes in lipids, endothelium-mediated 
vasodilatation, and arterial compliance, which phytoestrogens cause (Clarkson 2002).
Data on the effects of phytoestrogens on lipids and lipoproteins were put 
together in an extensive meta-analysis (Anderson et al. 1995). Soy protein (mean of 47 g/day) 
with isoflavonoids was associated with reductions in total cholesterol (9.3%), LDL 
cholesterol (12.9%) and triglycerides (10.5%), whereas the levels of HDL cholesterol showed 
no significant change (Anderson et al. 1995). The falls in total cholesterol and LDL 
cholesterol were the larger, the higher the initial serum cholesterol concentrations (Anderson 
et al. 1995). The benefits of soy protein on lipids were recognized by the FDA, which in 1999 
stated that “ 25 g of soy protein a day, as part of a diet low in saturated fat and cholesterol, 
may reduce the risk of heart disease” (Clarkson 2002).   
The benefits of soy protein on the serum lipid profile may appear to resemble 
those of HT (Godsland 2001), but unfortunately the data are far from being uniform (Nestel et
al. 1997, Simons et al. 2000, Teede et al. 2001, Dewell et al. 2002, Dalais et al. 2003). The 
discrepancies may be derived in part from differences in study populations or in 
phytoestrogen regimens used in various trials (Nestel et al. 1997, Simons et al. 2000, Teede et
al. 2001, Dewell et al. 2002, Dalais et al. 2003). Another possible vasoprotective mechanism 
may be the increased oxidation resistance of lipoproteins which isoflavones are known to 
induce (Tikkanen et al. 1998). Genistein (36 mg daily) and daidzein (21 mg daily) for two 
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weeks resulted in increased oxidation resistance of LDL (Tikkanen et al. 1998); this finding 
has been supported by some (Meng et al. 1999, Wiseman et al. 2000) although not by all 
studies (Hodgson et al. 1999, Samman et al. 1999). 
In addition to lipid benefits, isoflavones can contribute to vascular health 
through endothelium-mediated arterial dilatation and vascular elasticity (Anthony et al. 1998,
Clarkson 2002). Indeed, genistein has been shown to stimulate the release of NO in some 
animal experiments (Honoré et al. 1997, Squadrito et al. 2000) and recently also in women 
(Walker et al. 2001, Squadrito et al. 2002), but, on the other hand, no change in endothelial 
function was seen after isoflavonoid supplementation (80–118 mg/day) in postmenopausal 
women (Simons et al. 2000, Teede et al. 2001). In another study an improvement of 26% was 
registered in systemic arterial compliance during isoflavonoid use (Nestel et al. 1997).
Isoflavonoids may also inhibit thrombotic mechanisms and by this mode of action suppress 
promotion and progress of atherosclerosis (Anthony et al. 1998). 
Insulin resistance is a significant risk factor of CVD (Greenland et al. 2003).
Thus a regimen claimed to be protective against CVD, such as use of phytoestrogens, should 
increase insulin sensitivity. However, this aspect has not been thoroughly studied in healthy, 
non-diabetic humans, although in ovariectomized cynomolgus monkeys isoflavones together 
with soy protein improved insulin sensitivity (Wagner et al. 1997). Soy also improved insulin 
sensitivity in postmenopausal women with type 2 diabetes (Jayagopal et al. 2002), but not in 
healthy postmenopausal women in a small study of 18 subjects (Duncan et al. 1999).
Recent data imply that the baseline CRP level is a more accurate predictor of 
cardiovascular events than the LDL cholesterol level (Ridker et al. 2002). This protein stems 
from the liver, and its synthesis is stimulated by estrogens (Pradhan et al. 2002). Oral HT has 
been associated with moderate elevations in CRP levels in many (Cushman et al. 1999, Luyer 
et al. 2001, Pradhan et al. 2002, Strandberg et al. 2003, Ylikorkala et al. 2003a), although not 
in all studies (Zanger et al. 2000). During the design of the present study, no data existed on 
the effect of phytoestrogens on CRP.
6.5 Breast
It is established that the risk of Asian women developing breast cancer is smaller than that of 
Western women (Wu et al. 1998, Adlercreutz 2003, Peeters et al. 2003). One of the suggested 
explanations has been the high intake of phytoestrogens in Asian countries (Adlercreutz 2003, 
Peeters et al. 2003). This speculation is supported by the finding that the higher the soyfood 
consumption in adolescence, the lower is the risk of breast cancer (Wu et al. 1996, Shu et al.
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2001, Adlercreutz 2003). In addition, in some, although not all case-control studies, increased 
phytoestrogen intake has been associated with a decreased risk of breast cancer (Lee et al.
1991, Ingram et al. 1997, den Tonkelaar et al. 2001), although in a previous prospective 
cohort study in Holland high dietary intake of isoflavones was not related to decreased breast 
cancer risk (Keinan-Boker et al. 2004). However, a possible protective effect of isoflavones 
against breast cancer might be associated with a person’s ability to produce equol from 
daidzein in the gastrointestinal tract, as the risk of breast cancer has been lowest in subjects 
with high production of equol (Duncan et al. 2000). High equol production is a marker of 
high colonic bacterial activity, which may also increase steroid elimination to the feces and 
thereby reduce the levels of cancer-promoting endogenous hormones (Duncan et al. 2000).
However, phytoestrogens have so far failed to protect against breast cancer in postmenopausal 
women (Peeters et al. 2003).
Increased breast density is a risk factor of breast cancer (Clemons and Goss 
2001). In some small studies use of isoflavones has been accompanied by decreased breast 
density in postmenopausal women, implying perhaps a protective or at least a neutral effect 
on the breast (Messina and Loprinzi 2001). However, the influence of isoflavonoids could be 
dose-dependent; genistein at low concentrations stimulated, but at high concentrations 
inhibited the growth of an ER-positive mammary cancer cell line (Messina and Loprinzi 
2001). Isoflavones may operate through ERs in the breast, because ER-negative cells were not 
affected by genistein (Messina and Loprinzi 2001). Two-week soy supplementation (45 mg 
isoflavones/day) had an estrogenic effect on normal breast tissue in premenopausal women as 
measured by nipple aspirate apolipoprotein D and sS2 expression (Hargreaves et al. 1999), 
whereas no stimulation of breast secretion was seen in postmenopausal women after a six-
month soy diet (Petrakis et al. 1996).
Although no data suggest an increased risk of breast cancer in users of 
phytoestrogens, caution is still needed. This was also the conclusion in two recent reviews 
(Adlercreutz 2003, Peeters et al. 2003). Therefore, it is recommended that soy and isoflavones 
can be consumed by subjects with a history of breast cancer, but for a limited time period of 
6–12 months (Messina and Loprinzi 2001). 
6.6 Cognitive function 
It is well established that menopause is accompanied by deterioration of cognitive function, 
such as learning, memory, and concentration (Zandi et al. 2002), although it is open whether 
this is a menopause-related specific phenomenon, or just an age-dependent consequence. 
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Therefore, it is of interest that isoflavones (110 mg/day) for six months were associated with 
favorable effects on cognitive function, especially in verbal memory in postmenopausal 
women (Kritz-Silverstein et al. 2003). These clinical data seem to confirm the findings in 
estrogen-deficient rats, whose learning capacity was improved with isoflavones (Pan et al.
2000). However, cognitive functions are difficult to study objectively, especially in early 
postmenopausal women, who undergo dramatic changes in their hormonal milieu and also in 
their social surroundings. Clearly, much more research must be done before a possible effect 
of phytoestrogens on cognitive function in postmenopausal women can be proven. 
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AIMS OF THE STUDY 
The present study was undertaken to investigate the usefulness of phytoestrogens in the 
treatment of menopause. The specific aims were to study the effects of isolated isoflavonoids 
on:
1. climacteric symptoms and quality of life 
2. vaginal and endometrial epithelium 
3. markers of bone metabolism 
4. lipids, lipoproteins, insulin sensitivity and ghrelin 
5. vascular surrogate markers 
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SUBJECTS AND METHODS 
1. SUBJECTS
This prospective study was carried out at the Department of Obstetrics and Gynecology, 
Helsinki University Central Hospital, during 1999–2001. The study protocol was approved by 
the Ethics Committees of both the Department of Obstetrics and Gynecology, and Oncology, 
and the subjects gave informed consent prior to participation. Study subjects (n = 64) were 
postmenopausal women with incapacitating climacteric complaints and a history of breast 
cancer. Each woman had been operated upon because of breast cancer more than six months 
earlier and was devoid of any metastasis at recruitment, which was carried out between the 1st
of September 1999 and the 10th of October 2000. Thirteen women (11 premenopausal and 2 
postmenopausal) had received chemotherapy, at a mean of 5 years before recruitment and 
three subjects had used tamoxifen for 2 months to 4 years, but this treatment had been 
discontinued 5 months to 4 years before recruitment. Before the diagnosis of breast cancer, 22 
patients (39.3%) had used some form of HT (Table 7).  
Table 7. Clinical characteristics of the study population (n=56) 
Age (yr) 54 ? 6 (35–69) 
Age at menopause (yr) 49 ? 4 (34–55) 
Body Mass Index (BMI) (kg/m2) 26.3 ? 3.3 (21.2–33.6) 
Smoking 13 (23%) 
Previous use of HT 22 (39%) 
History of hysterectomy 10 (18%) 
Systolic blood pressure (mm Hg) 134.9 ? 19.7 (101–170) 
Diastolic blood pressure (mm Hg) 87.2 ? 10.3 (60–109) 
FSH (U/L) 80.6 ? 32.0 (30.9–166.5) 
Other diseases 






Values are mean ? SD (range) or n (%). 
The inclusion criteria were 1) lack of residual breast cancer or metastasis, 2) 
incapacitating climacteric complaints such as hot flashes, night sweats, and sleeplessness, and 
3) a level of FSH exceeding 30 U/L. The exclusion criteria were 1) use of sex steroids or 
tamoxifen, 2) use of natural products with presumed estrogenic activity, 3) use of drugs 
possibly affecting climacteric symptoms, metabolism, or absorption of phytoestrogens (e.g.
antibiotics during the previous 3 months), 4) use of statins, and 5) history of any 
thromboembolic or hepatic event.  
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Eight women took antihypertensive drugs (three women, calcium-channel 
blockers; two women, beta-blockers; one woman, diuretics; one woman, calcium-channel 
blocker + angiotensin-convertase inhibitor, and one woman, diuretic + calcium-channel 
blocker). Six women used thyroxine and seven used antidepressive medication (five of them, 
selective serotonin-reuptake inhibitors, one a selective monoamine oxidase (MAO) inhibitor 
combined with amitriptyline, and one MAO inhibitor only). During the trial, 13 women 
needed to use antibiotics for acute infection: seven of them during the phytoestrogen regimen, 
four during the placebo period, and two during both treatment periods. In addition, two 
patients intermittently used trimethoprim for prophylaxis of urinary infection during both 
regimens; none of these 15 patients were excluded.   
2. STUDY PROTOCOL
Following a double-blind, crossover technique, the women were treated in computer-
randomized order either with isoflavonoids or placebo. Each treatment lasted three months, 
and the treatment phases were interrupted by 2-month washout periods. We screened 64 
women; two were excluded, one because her FSH level was below 30 U/L and the other 
because she had taken an antibiotic course within three months before the study. Of the 62 
women eligible for randomization, 32 women were to start with phytoestrogens and 30 with 
placebo (Figure 2). Six women discontinued the trial during the first treatment regimen – four 
in the phytoestrogen group (two because of stomach ache, one for personal reasons and one 
because of recurrence of breast cancer) and two in the placebo group (one because of lack of 
effect and one because of vaginal bleeding). Thus, 56 women completed the study (Figure 2, 
Table 7). One woman was excluded from the final analysis in Study III because she had used 
alendronate. Six women exhibited 14 CRP values over 5 mg/L, and these values were 
excluded from the final analysis in Study V. 
Before starting this trial we carried out a pilot study on 54 healthy 
postmenopausal women to determine the adequate dose of phytoestrogens (Kilkkinen et al.
2000). Daily administration of 58 mg of isoflavones (Bonette?, Novomed, Helsinki, Finland) 
resulted in 20- to 35-fold rises in the circulating levels of phytoestrogens, with moderate 
interindividual variations. As this dose was well tolerated, we decided to increase the dose to 
114 mg/day in the present study to guarantee adequate dosage. Isoflavonoid tablets and 
similar looking placebo tablets were to be taken every 12 hours (3 tablets) with a glass of 
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water. Each isoflavonoid tablet consisted of glycitein (11 mg, 58%), daidzein (7 mg, 36%), 
and genistein (1 mg, 6%).  
The subjects were seen at the research center immediately before and on the last 
day of each treatment period. General and pelvic examinations including transvaginal 
ultrasonography were performed and appropriate blood and urine samples, vaginal and 
cervical smears, and endometrial biopsies were collected. At each visit the women were 
carefully interviewed about hot flashes and other typical climacteric symptoms and they 
recorded their menopausal symptoms on the Kupperman scale. In addition, we asked the 
women to assess the total severity of the menopausal syndrome with the aid of a 10 cm-long 
visual analogue scale (VAS).  
The women were also asked to rate their physical and mental working capacity 
in a previously established diary employing five targeted questions on a scale from very poor 
(1) to very good (5). In addition, they rated their present overall work capacity as compared 
with their lifetime best on a scale of 0 to 10. The scores from these six questions were 
balanced and summed up and used as the Work Ability Index, as described before (Tuomi et
al. 1994). A score of 3 to 13 indicated poor working capacity, 14 to 17 moderate, 18 to 21 
good and 22 to 24 excellent working capacity (Tuomi et al. 1994).
Depressive mood, anxiety, and the level of self-confidence were recorded by use 
of established indexes (Raitasalo 1995). Depression was assessed with 13 questions 
concerning mood, social behavior, and opinion of the future. Each answer was rated on a 
scale from 0 (most positive) to 3 (most negative). A sum of 5 to 7 was judged to indicate mild 
depression, between 8 and 15, moderate depression, and over 16, severe depression (Raitasalo 
1995). In addition, anxiety and self-confidence were separately determined by means of 
specific questions (Raitasalo 1995). At the end of the last treatment period, each woman was 
invited to indicate her preference as regards the two treatments.  
During the study the women were encouraged to lead normal lives with no 
changes in dietary habits, alcohol consumption or physical activity, which were all recorded 
by means of questionnaires before and at the end of each treatment period. The women kept 
weekly diaries concerning their general health, bleeding, use of antibiotics or any other 
concomitant drugs, and possible side effects. We did not provide calcium or vitamin D 
supplementation, but eight women used calcium supplementation and three women took 
vitamin D supplements; they were advised to continue these during the trial. 
Compliance with use of the study medication was confirmed by checking the 
diaries and by analyzing the serum levels of isoflavonoids – daidzein, genistein and equol. 
    40
N = 64 
Isoflavonoid regimen 
3 months
N = 28 
N = 62 
N = 32 




?? 2, stomach ache 






?? 1, vaginal 
bleeding 
?? 1, lack of effect
Screening
    
2 excluded 
?? 1, antibiotic use within 3 months 
before recruitment 
?? 1, FSH ? 30 U/L 
Randomization,     
Blood samples 






      
Assessment 
Blood samples 
FSH = follicle-stimulating hormone 
BC = breast cancer 
Figure 2. Design and conduct of the trial
3. MEASUREMENTS
3.1 Blood and urine samples 
The samples were collected after an overnight fast. The use of food rich in nitrate (red meat, 
sausages, red beet and spinach) was not allowed for 48 hours before blood sampling. Serum 
was separated by centrifugation, and samples of serum and urine were stored frozen (-20 °C) 
until assayed. An oral 2-h glucose tolerance test (75 g) was carried out at baseline and at 3 
N = 28 
N = 30 
N = 28 N = 28 
N = 28 
Placebo regimen 
3 months 
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months of both treatments in the first 20 subjects. Blood glucose and insulin levels were 
assessed immediately. 
The blood and urine samples in Studies I, II, III and V were assayed by means 
of established methods, the details of which are given in Table 8. Aliquots of serum were also 
assayed for aspartate transaminase (ASAT), alanine transaminase (ALAT) and creatinine by 
routine laboratory methods.  
Table 8. Characteristics of the assays 












Wang et al. 2000 5–7  8–12  
FSH  Solid phase 
fluoroimmunometric assay 





Delfia, Wallac Oy, Turku, 
Finland 
2 4 
Estradiol Solid phase 
fluoroimmunometric assay 

































Beckman Coulter, Fullerton, 
CA, in Limbach, Germany 








C-reactive protein Sensitive immunochemical 
assay using monoclonal 




E-selectin Sandwich enzyme 
immunoassay 
R&D Systems, Minneapolis, 
MN 
< 5 < 9 
NOx Griess reaction and 
spectrophotometry 
Viinikka 1996 3 11 
CV=Coefficient of variation, FSH=follicle-stimulating hormone, LH=luteinizing hormone, SHBG=sex 
hormone-binding globulin, NTx=N-terminal cross-linked telopeptide of type I collagen, Pyr=pyridinoline, 
Dpyr=deoxypyridinoline, BAP=bone-specific alkaline phosphatase, PINP= amino-(N-)terminal procollagen type 
I, PICP=carboxy-(C-)terminal procollagen type I , NOx = nitrate-nitrite 
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Serum total cholesterol and triglyceride concentrations were determined by 
enzymatic colorimetric methods (Study IV) (Roche, Basel, Switzerland). LDL and HDL-2 
cholesterol were separated from serum by sequential ultracentrifugation. The total HDL 
fraction was obtained by the heparin-manganese chloride precipitation method. Levels of 
apolipoprotein B and apolipoprotein A1 were determined by immunochemical methods 
(Orion Diagnostica, Espoo, Finland). The concentrations of lipoprotein (a) (Lp(a)) were 
determined by an immunoturbidimetric method (WAK Chemie, Steinbach, Germany). All 
these lipids were assessed in every subject except for LDL and HDL-2 cholesterol, which 
were assessed in only the first 20 subjects. Blood samples for assay of glucose and insulin 
were drawn before and at 1 and 2 hours after the intake of glucose (75 g). Blood glucose 
concentrations were determined by the hexokinase method (Roche Diagnostics GmbH, 
Mannheim, Germany), the coefficients of intra- and interassay variation being between 2–4%. 
Serum insulin levels were quantified by double antibody solid phase radioimmunoassay 
(Phadeseph? Insulin RIA, Kabi Pharmacia Diagnostics, Uppsala, Sweden). The detection 
limit of the assay was 2.5 mU/L. The intra- and interassay coefficients of variation were 3–
9%. Cross-reaction with C-peptide was below 0.1%. 
3.2 Pap smears 
Cells from the vagina, cervix and endocervix were collected in order to evaluate the vaginal 
epithelium objectively (Study II). Cells from the vagina were collected with a wooden spatula 
and from the cervix with a brush. The smears were fixed in 95% ethyl alcohol and the slides 
stained by means of the modified Papanicolaou method. Vaginal cells (n = 200) from each 
slide were examined and classified as parabasal, intermediate and superficial cells. The 
maturation index (MI) was calculated as the sum of the percentage of superficial cells plus 
half of the percentage of intermediate cells. All cytological samples were evaluated by the 
same cytologist, who was blind to the treatment. 
3.3 Markers of endometrial proliferation 
Endometrial thickness was measured by transvaginal ultrasonography (Hitachi EUB-525 with 
a 5 MHz transvaginal transducer, Tokyo, Japan) in the anteroposterior direction from the 
echogenic interface of the endometrial-myometrial junction on both sides (Study II).  
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After transvaginal ultrasonography, endometrial samples were taken with 
disposable biopsy curettes (Pipelle, Laboratoire CCD, Paris, France). The samples were fixed 
in formalin and embedded in paraffin for histological and immunohistochemical analyses. All 
biopsy samples were examined by the same pathologist. The estrogenic effect on the 
endometrium was evaluated on a four-point scale: 0 = totally atrophic, 1= minimal estrogenic 
effect, 2 = modest estrogenic effect and 3 = proliferation. Scores of 0 and 1 were considered 
atrophic. Expression of ER, PR and that of the proliferation marker Ki-67 in the endometrial 
samples was examined by means of immunohistochemistry. Monoclonal mouse antibodies 
that detect human ER? (DAKO ER, Dako, Denmark), PR A and B (Novocastra Laboratories 
Ltd., Newcastle-upon-Tyne, UK) and Ki-67 (Pharmingen, San Diego, CA, USA), were used 
as previously described (Hurskainen et al. 2000). The immunohistochemical data were 
analyzed by two independent observers by means of subjective semiquantitative scoring. In 
negative controls the primary antibody was replaced with nonimmune mouse serum of 
equivalent concentration. Ten fields of cells of a tissue section (magnification ×200) were 
examined, and only nuclear staining was considered specific to ER, PR and Ki-67. The 
expression of ER and PR was based on staining intensity and the distribution of positive-
staining cells was graded as follows: 0 = absent, 1 = weak, 2 = moderate and 3 = intense, and 
as regards Ki-67, 0 = not detectable, 1 = detectable. For further statistical analysis the scale of 
expression of ER and PR was modified as follows: grades 0 and 1 = class 1, and grades 2 and 
3 = class 2. As isoflavonoids could potentially act differently on epithelial and stromal cells, 
the expression of ER, PR and Ki-67 was scored separately in the endometrial epithelial and 
stromal cells. 
4. STATISTICAL ANALYSES
A sample size of 54 women was calculated to have 95% power to detect a 40% difference 
between treatments in mean number of hot flashes, with standard deviation (SD) of 2.2. As we 
used a crossover design, the possibility of a period effect was tested by means of the unpaired
t-test (for parametric data) or the Mann-Whitney test (for non-parametric data), where we 
compared the differences between the periods in the two groups of subjects (those beginning 
with the phytoestrogen and those beginning with the placebo). No period effect was detected. 
The possibility of treatment-period interaction was also investigated by means of the unpaired
t-test or the Mann-Whitney test, where we compared the average responses to the two 
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treatments; the subjects’ average responses to the two treatments were unrelated to the order of 
the treatments.  Thus, no carry-over effect was detected for any variables measured.  
The data are presented as mean ? SD except where stated otherwise. Paired t-
tests or non-parametric tests (sign or Wilcoxon Signed Ranks test) were used to determine any 
changes (difference between post-treatment and baseline values) in the main variables 
(Studies I, II, III, and V), and these tests were also used to compare the effects of the two 
treatments. Additionally, the McNemar test was used to assess changes in Ki-67 and the 
Marginal Homogenicity test was used to assess changes in estrogenic effect on endometrial 
histology, and endometrial expression of ER and PR between baseline and post-treatment 
values (Study II). Comparison of the two treatments (isoflavonoid vs. placebo) was carried 
out by repeated measures analysis of variance (RM ANOVA) using a general linear model, 
and differences between baseline and post-treatment values were analyzed by means of the 
paired t-test (Study IV). Levels at baseline in all studies were compared by using either the 
unpaired t-test or the Mann-Whitney U-test. Correlations between variables were calculated 
by means of Pearson’s parametric (Study IV) or Spearman’s nonparametric correlation 
analysis (Studies III and V). The X2 test was used to analyze the subjects’ preference for 
treatments (Study I).  
Because the levels of equol, which is exclusively produced by intestinal bacteria 
from precursor isoflavonoids of dietary origin, may determine the health effects of soy 
isoflavonoids (Setchell et al. 2002), we also carried out a subgroup analysis based on pretrial 
levels of equol (below median = “low” producers; above median = “high” producers) (Study 
I) and on levels of equol at 3 months of isoflavonoid use (“equol producer” = equol 
concentration above 83 nmol/L and “nonequol producer” below 40 nmol/L) (Study IV). 
A p-value of less than 0.05 was considered significant. Statistical analyses were 
performed by using SAS (SAS Institute Inc., Cary, NC) or SPSS 10.0/11.0 (SPSS Institute, 
Inc., Chicago, IL, USA) statistical packages. 
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RESULTS
Detailed results are given in the original publications and are therefore only briefly 
summarized here.
1. LEVELS OF ISOFLAVONOIDS, CLIMACTERIC SYMPTOMS, AND QUALITY OF LIFE (STUDY I)
Fifty-six out of the 62 randomized women (90.3%) completed the 8-month study. The use of 
isoflavonoids led to significant rises in circulating levels of daidzein (1059.6 ± 782.5 nmol/L, 
a mean 106-fold rise), genistein (403.8 ± 275.7 nmol/L, 20-fold rise) and equol (39.3 ± 78.3 
nmol/L, 19-fold rise), whereas the placebo regimen had no effect (Figure 3).  
The Kupperman index at baseline ranged from 5 to 42 and was similar in 
women randomized to start first with isoflavonoids (27.0 ± 8.6) or with placebo (27.5 ± 9.3) 
(Table 9). The isoflavonoid regimen reduced the Kupperman index by 4.2 ± 9.6 scores 
(15.5%) (p = 0.002), but this reduction did not differ from that during placebo treatment (4.0 
± 8.1, 14.7%). Thus Kupperman indexes at the end of isoflavonoid and placebo treatment did 
not differ (Table 9). Neither hot flashes nor any other components of the Kupperman index 
were relieved by the isoflavonoid regimen when evaluated separately. The total severity index 
of menopausal symptoms on the VAS scale ranged from 8 to 89 mm before the trial (55.7 ± 
20.0), from 1 to 100 mm (46.5 ± 26.5) during isoflavonoid use and from 3 to 100 mm (49.3 ± 
23.1) during placebo use (p = 0.851, NS).
Isoflavonoids had no effect on working ability, depression, anxiety or self-
confidence (Table 9). The data were also analyzed in regard to baseline equol levels (“low” 
equol producers, n = 28, 1.41 ± 0.42 nmol/L and “high” equol producers, n = 28, 4.22 ± 4.42 
nmol/L). The basal equol level was not a determinant of the effect of isoflavonoids on any of 
the variables measured. 
The phytoestrogen regimen was well tolerated. Twenty-five women (44.6%) 
preferred the isoflavonoid regimen and 15 women (26.8%) the placebo (NS), whereas 16 
(28.6%) women had no preference for either treatment. 
The isoflavonoid regimen did not affect the levels of FSH, LH, estradiol or 
SHBG (Table 10). Neither did it affect ASAT, ALAT, creatinine, blood pressure or body 
mass index. 


























Figure 3. Mean (? SD) levels of daidzein, genistein, and equol before and after 3 months’ use of isoflavonoid or 
a placebo 
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Table 9. Kupperman-index, menopausal visual analogue scale (VAS), and separate indexes for hot flashes*, 
work ability, depression, anxiety, and self-confidence before and at the end of isoflavonoid and placebo 
treatment for 3 months 
Variable Before After Change p-value in comparison with 




27.0 ± 8.6 
27.5 ± 9.3 
22.8 ± 10.1 
23.5 ± 8.4 
-4.2 ± 9.6 







52 ± 23 
56 ± 22 
47 ± 27 
49 ± 23 
-6 ± 29 




Index for hot flashes 
Isoflavonoid  
Placebo
2.0 ± 0.9 
2.1 ± 0.8 
1.8 ± 1.0 
1.8 ± 0.9  
-0.2 ± 1.1 




Work ability index 
Isoflavonoid  
Placebo
16.8 ± 3.9 
16.2 ± 3.9 
16.8 ± 3.5 
16.8 ± 3.6 
-0.1 ± 2.8 







6.1 ± 5.0 
5.7 ± 4.5 
4.6 ± 4.4 
4.4 ± 4.2 
-1.5 ± 2.9 







1.6 ± 1.5 
1.4 ± 1.6 
1.4 ± 1.6 
1.5 ± 1.6 
-0.2 ± 1.5 







4.3 ± 3.3 
3.9 ± 3.3 
4.5 ± 3.6 
4.4 ± 3.3 
0.3 ± 2.5 




* (0 = absent, 1 = weak, 2 = moderate, 3 = severe)
Table 10. Circulating levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) and 
sex hormone-binding globulin (SHBG) before and after isoflavonoid or placebo treatment for 3 months (mean ± 
SD). No differences in these levels reached statistical significance 




79.9 ? 34.5 
78.8 ? 31.3 
79.5 ? 32.0 




32.6 ? 12.2 
32.4 ? 12.3 
31.9 ? 12.6 




0.140 ?  0.085 
0.127 ?  0.085 
0.138 ?  0.144 




69.1 ? 26.0 
75.3 ? 28.1 
70.6 ? 27.8 
71.5 ? 29.9 
2. VAGINA AND ENDOMETRIUM (STUDY II)
The isoflavonoids did not relieve vaginal dryness (baseline score 1.7 ± 1.0; at 3 months 1.6 ± 
1.1; change -0.06 ± 0.9, p = 0.327). Neither did it have any effect on MI, whereas this slightly 
deteriorated during the placebo regimen (-5.6 ± 17.2, p = 0.031). There were no changes in 
the percentages of cells in the parabasal, intermediate and superficial layers during the 
isoflavonoid regimen (Figure 4).




























Figure 4. The percentages of parabasal, intermediate and superficial cells in Pap smears before and at the end of 
isoflavonoid and placebo treatment for 3 months (n=56)
Endometrial thickness did not change during the isoflavonoid (2.4 ± 1.5 mm at 
baseline, 1.9 ± 0.8 mm at 3 months, p = 0.090) or the placebo regimen (2.1 ± 1.1 vs. 2.2 ± 1.4, 
p = 0.877). Moreover, the isoflavonoid treatment affected neither endometrial histology nor 
the expression of ER, PR or Ki-67. 
3. MARKERS OF BONE TURNOVER (STUDY III)
Of the bone resorption markers, the isoflavonoid regimen failed to affect the urinary output of 
NTx significantly, although it resulted in a trend towards its reduction (Table 11, Figure 5). 
The outputs of Pyr and Dpyr were reduced from baseline by 9 and 5% after the isoflavonoid 
regimen, respectively. Compared with the placebo group, the fall in Dpyr was significant (p =
0.022) and the falls in Pyr (p = 0.084) and NTx (p = 0.082) showed a trend towards 
significance (Table 11). The higher the level of any biochemical bone marker at baseline, the 
larger the reduction during the isoflavonoid regimen (p < 0.01).
Bone formation markers, such as BAP, PINP and PICP, were not affected by the 
isoflavonoid regimen (Table 11). 
The increases in circulating genistein and equol levels did not correlate with 
changes in the concentrations of any bone resorption or formation marker, whereas elevation 
of the serum daidzein level was in direct correlation with falls in the concentrations of Pyr 
(Spearman’s correlation coefficient = 0.315; p = 0.024), PINP (Spearman’s correlation coef-
ficient = 0.272, p = 0.047) and PICP (Spearman’s correlation coefficient = 0.272; p = 0.047). 
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Table 11. Urinary output of the N-terminal cross-linked telopeptide of type I collagen (NTx), pyridinoline and 
deoxypyridinoline and serum levels of bone-specific alkaline phosphatase (BAP), procollagen type I N-terminal 
propeptide (PINP) and procollagen type I C-terminal propeptide (PICP) before and after isoflavonoid or placebo 
treatment for 3 months 


















































































































Values are mean (SD). 
1 p ? 0.05 in comparison of 0 and 3 months, 2 p ? 0.05 in comparison of isoflavonoid and placebo 
















Falls in Pyr and Dpyr during isoflavonoid are significant (p < 0.05). 
Figure 5. Percentual changes in the urinary output of the N-terminal cross-linked telopeptide of type I collagen 
(NTx), pyridinoline (Pyr) and deoxypyridinoline (Dpyr) (mean ± SE) in women using isoflavonoids or placebo 
for three months 
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4. LIPIDS, LIPOPROTEINS AND INSULIN SENSITIVITY (STUDY IV)
The isoflavonoid regimen did not affect the levels of the various lipids assayed (Table 12). 
However, during the isoflavonoid regimen women with pre-study LDL cholesterol levels 
above the median (4.20 mmol/L) showed a rise in LDL cholesterol (0.65 ± 0.60 mmol/L), 
which was statistically different from the change during the placebo regimen (fall of 0.45 ± 
0.67 mmol/L, p = 0.009). The change in LDL cholesterol was not correlated with the baseline 
LDL cholesterol level. 
Fasting and post-load levels of glucose and insulin were not affected by the 
isoflavonoid regimen. The changes in levels of ghrelin were significantly different (p = 0.048) 
during the isoflavonoid (-7.1 ? 151 ?mol/L) vs. the placebo regimen (+47.9 ? 198 ?mol/L).
Being an “equol producer” (n = 8) or “nonproducer” (n = 40) was not a factor as 
regards the effects of isoflavonoids on lipids and insulin sensitivity. 
Table 12. Levels and changes from basal levels in absolute units of total cholesterol, low-density lipoprotein 
cholesterol (LDL), total high-density lipoprotein cholesterol (HDL) and its fraction 2 (HDL-2), triglycerides, 
apolipoprotein B (Apo B), apolipoprotein A1 (Apo A1) and lipoprotein (a) (Lp(a)) before and after isoflavonoid 
or placebo treatment for 3 months
Variable Isoflavonoid   Placebo   




5.88 ± 0.97 6.02 ± 1.46 0.14 ± 0.95 5.83 ± 1.04 5.91 ± 1.13 0.06 ± 0.67 
LDL
(mmol/L) 
3.87 ± 0.93 4.08 ± 1.17 0.28 ± 0.63 3.80 ± 1.17 3.74 ± 0.86 -0.06 ± 0.68 
HDL
(mmol/L) 
1.78 ± 0.45 1.76 ± 0.39 -0.03 ± 0.26 1.77 ± 0.38 1.76 ± 0.39 -0.008 ± 0.27 
HDL-2
(mmol/L) 
0.87 ± 0.40 0.85 ± 0.40 -0.04 ± 0.29 0.84 ± 0.38 0.84 ± 0.38 0.007 ± 0.28 
Triglycerides 
(mmol/L) 
1.22 ± 0.57 1.24 ± 0.59 0.02 ± 0.48 1.25 ± 0.53 1.26 ± 0.65 0.005 ± 0.39 
Apo B 
(g/L)
1.10 ± 0.24 1.13 ± 0.33 0.023 ± 0.21 1.12 ± 0.27 1.10 ± 0.28 -0.02 ± 0.18 
Apo A1 
(g/L)
1.58 ± 0.23 1.58 ± 0.22 0.003 ± 0.24 1.55 ± 0.17 1.56 ± 0.26 0.005 ± 0.25 
Lp(a) 
(mg/L)
171.2 ± 204.8 179.9 ± 233.2 8.7 ± 66.9 171.4 ± 221.4 162.8 ± 200.8 -8.6 ± 79.1 
Values are mean ± SD. No changes were statistically significant
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5. C-REACTIVE PROTEIN, E-SELECTIN AND NITRATE (STUDY V)
The isoflavonoid regimen did not affect the levels of CRP or NOx, when analyzed in regard to 
changes from basal levels or changes in the placebo group (Table 13). However, it was 
associated with a reduction in the levels of E-selectin (4.0% drop; p = 0.031) from baseline to 
three months. The placebo regimen was also associated with a decline (2.2% drop; p = 0.023) 
in E-selectin levels. Thus, E-selectin concentrations at three months did not differ between the 
isoflavonoid and placebo regimens (p = 0.894) (Table 13). When E-selectin levels at 0 and 5 
months were compared, a p-value of 0.073 suggested there might have been some carry-over 
effect.
Increases in daidzein and genistein levels were in direct relationship with 
reductions in E-selectin levels (Spearman’s correlation coefficient 0.391, p = 0.003, and 
0.382, p = 0.004, respectively), but not with changes in CRP or NOx.
Table 13. Levels of C-reactive protein (CRP), E-selectin and nitrate-nitrite (NOx) before and at the end of 
isoflavonoid and placebo treatment for 3 months (n=56) 
Variable Before After Change p-value for changes 
compared with




1.16 ± 1.03  
1.10 ± 0.79 
1.10 ± 0.91 
1.10 ± 0.84 
-0.07 ± 0.95 









42.7 ± 17.5   
42.6 ± 18.3 
41.3 ± 17.3 
-2.9 ± 9.6 







23.1 ± 16.5 
22.7 ± 10.0 
25.5 ± 16.5 
25.8 ± 16.5  
 2.7 ± 13.2 




Values are median ± SD. 
1 Difference between the isoflavonoid group and the placebo group at 0 months, p=0.011 
2 p < 0.05 significance for the change from baseline
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DISCUSSION 
We studied the effects of isoflavonoids on postmenopausal women with a history of breast 
cancer. There were two main reasons for selecting this population. First, such women are 
often advised against the use of HT, although they suffer from typical climacteric symptoms 
(Consensus statement 1998). Second, randomization of symptomatic postmenopausal women 
with no contraindications for HT to a placebo regimen or to a regimen the effect of which is 
unknown (such as isoflavonoids) may present an ethical dilemma, because HT is an effective 
and safe treatment, at least in short-term use, for these symptoms (MacLennan et al. 2001). 
Thus, studying women with treated breast cancer overcomes these dilemmas. We feel that our 
treatment was safe towards breast tissue in these women, and this opinion is supported by 
others (Messina and Loprinzi 2001) and by two ethics committees in our university central 
hospital.
Apart from a history of breast cancer, our study subjects resembled healthy 
postmenopausal women entering menopause normally. Only eleven women had received 
chemotherapy while they still were premenopausal, and this may have prompted the onset of 
menopause in these individuals; however, their menopause, with its hormonal changes and 
symptoms, was comparable with that in the other study subjects. In addition, we did not 
approve women using tamoxifen, because it may trigger hot flashes that may not be totally 
comparable with physiological ones (Marttunen et al. 2001) and because tamoxifen may 
stimulate the endometrium (Gorodeski et al. 1992, Tomás et al. 1995, Marttunen et al. 2001).
At baseline, two of the three women with a history of tamoxifen use showed atrophic 
endometrium, and the third one showed a moderate estrogenic effect but a thin endometrium 
(3.4 mm) in ultrasonography. This confirmed that a possible effect of tamoxifen on the 
endometrium had vanished in these women. Furthermore, the levels of lipids and lipoproteins 
in our subjects fell within the normal range for Finnish postmenopausal women (Ranta et al.
2002). Moreover, it is unlikely that a history of breast cancer without any concomitant use of 
chemotherapy or tamoxifen could modify lipid levels or endothelial function. Thus, we 
believe that our subjects represented healthy postmenopausal women as regards climacteric 
symptoms, lipids, lipoproteins, insulin sensitivity, and endothelial function. 
From our pilot study (Kilkkinen et al. 2000) we learnt that 58 mg of 
isoflavonoids consistently raised the circulating levels of daidzein, genistein and equol, so we 
were certain that the dose of 114 mg of isoflavonoids selected for the present trial was large 
enough to significantly raise the circulating levels of isoflavones; this was confirmed in the 
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present study. This dosage clearly exceeded the amount of phytoestrogens present in a typical 
Asian diet (20–80 mg/day) (Tham et al. 1998, Somekawa et al. 2001), but it was comparable 
with dosages used in some other studies (Kotsopoulos et al. 2000, Quella et al. 2000, Dewell 
et al. 2002, Han et al. 2002, van Patten et al. 2002, Dalais et al. 2003, Penotti et al. 2003). We 
mainly gave glycitein (66.1 mg/day), but also daidzein (41.1 mg/day) and genistein (6.8 
mg/day). Because the isoflavonoids were given concomitantly, it is impossible to draw any 
conclusions as regards the effect of any of these isoflavonoids separately. It is possible that 
they interact in the blood or in binding to ERs in different target tissues. Therefore, on the 
basis of our data we cannot exclude the possibility that treatment with a single isoflavonoid 
might have had a different effect than our regimen. However, the commercial isoflavone 
supplements available are all combinations of different isoflavonoids, and it is these 
combinations that postmenopausal women frequently use in attempts to relieve 
postmenopausal symptoms. Therefore, we feel that this combination was a proper object of 
study.
The tablets were taken twice a day. This should have resulted in relatively 
steady-state levels of isoflavones quickly, because peak plasma concentrations of isoflavones 
are attained 5–6 hours after oral ingestion and the half-life of systemic elimination is in the 
range of 6–8 hours (Setchell 2001, Setchell et al. 2001). We also believe that three months’ 
exposure to isoflavonoids was likely to be long enough to reveal any effect on the variables 
measured, excluding bone formation markers, which usually require at least 6 months to be 
affected by different hormones or drugs (Delmas 2000). Moreover, the effects of 
isoflavonoids are thought to resemble those of HT as regards vasomotor symptoms, the 
vagina, endometrium, and markers of bone metabolism and vascular health. The fact that the 
effects of HT are well recognized in 4 to 12 weeks (Brussaard et al. 1997, Chesnut et al.
1997, Cardozo et al. 1998, van Baal et al. 1999, Delmas 2000, Godsland 2001, North 
American Menopause Society 2004,) may be seen as further support for the claim that three 
months’ use of isoflavonoids should reveal at least their most significant effects on various 
target tissues. 
As regards climacteric symptoms, working ability, depression, anxiety and self-
confidence, we found no effect of isoflavonoids, although the isoflavonoid regimen was 
preferred by 25 women (44.6%). Our findings concur with the results of most of the 
randomized placebo-controlled studies published after the start of our trial (Quella et al. 2000, 
Penotti et al. 2003, Tice et al. 2003) (Table 14A). Our results are not in line with those of two 
earlier studies, one with 39 subjects who used isoflavonoids (50 mg/day) only for 6 weeks  
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Table 14. Randomized placebo-controlled studies on the effects of phytoestrogens on hot flashes 
A. Isolated isoflavonoids 
Researchers Isoflavonoid 
Source, dose/day 
Study design Number Results: 
Change of 




Quella 2000 et al.  Soy, 150 mg Double-blind, crossover, 4 
weeks, BC, 77% on 
tamoxifen 
177 ? 22 – ? 31 NS 
Scambia et al.
2000 
Soy, 50 mg Double-blind, 
6 weeks 
39 ? 44 – ? 24 < 0.01 
Upmalis et al.
2000 
Soy, 50 mg Double-blind, 
12 weeks 
177 ? 28 – ? 19 NS 
(0.078) 
Faure et al. 2002 Soy, 70 mg Double-blind,  
4 months 
75 ? 61 – ? 21 0.01 
Van de Weijer et
al. 2002 
Red clover, 80 mg Double-blind,  
8 weeks 
30 ? 44 – ? 0 < 0.01 
Nikander et al. 
2003 
Soy, 114 mg Double-blind, 12 weeks 62 ? 10 – ? 14 NS 
Penotti et al. 2003 Soy, 72 mg  Double-blind, 
6 months 
62 ? 40 – ? 40 NS 
Tice et al. 2003 Red clover, 57 mg 
and 82 mg 
Double-blind, 12 weeks 252 ? 34 –? 41  
– ? 36 
NS
B. Whole soy or supplements with isoflavonoids + soy protein 
Researchers Phytoestrogen 
Dose/day 
Study design Number Results: 












94 ? 6  – ? 2 NS 
St Germain et
al. 2001 
Soy protein isolate with 4.4 
mg or 80.4 mg isoflavones  
Double-blind, 24 
weeks
69 ? 3 – ? 49  
– ? 44 
NS
Balk et al. 2002 Soy cereal with 
92 mg isoflavones 
Double-blind, 
6 months 
27 ? 35 – ? 61 NS  
Han et al. 2002 Soy supplements with 
100 mg isoflavones 




82 ? 27 – ? 0 0.01 
Van Patten et
al. 2002 
Soy beverage with 90 mg 
isoflavones 
Double-blind, 12 
weeks, BC, 31% on 
tamoxifen  
157 ? 30 – ? 40 NS 
Burke et al.
2003 
25 g soy protein,  
with 42 mg or 58 mg 




241 ? 42 – ? 60  
– ? 77 
NS
Nahas et al. 
2004 




50 ? 44 – ? 10 <0.05 
p-value is in comparison with placebo/control. 
BC = breast cancer 
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(Scambia et al. 2000) and the other one where almost one third of the subjects discontinued 
the trial (Faure et al. 2002) (Table 14A). The inconsistency of the data has been explained by 
the presence of soy protein (soy diet) or its lack (isolated isoflavonoids), although the clinical 
effects seem to be of the same magnitude with (Table 14B) or without (Table 14A) soy 
protein. The initial and very promising data were often obtained from trials using no placebo 
control, which casts doubts on the specificity of the claimed benefit.  
The use of isoflavonoids had no objective beneficial effect on vaginal dryness in 
our subjects. This is not in line with the results of some other studies suggesting that soy 
isoflavones (100–118 mg/day) (Kotsopoulos et al. 2000, Han et al. 2002) alleviated vaginal 
dryness. It should also be noted that isoflavonoids have had no effect on vaginal epithelium in 
most previous studies (Albertazzi et al. 1999, Baber et al. 1999, Duncan et al. 1999, Scambia 
et al. 2000, Upmalis et al. 2000), although the data are not uniform (Wilcox et al. 1990, Baird 
et al. 1995, Dalais et al. 1998). Moreover, our isoflavonoid regimen was not accompanied by 
any estrogenic effects in the endometrium, which we investigated with the aid of 
ultrasonography, histology and the expressions of markers reflecting endometrial reactivity to 
various steroid hormones. It was known before that isoflavonoid supplements (40–132 
mg/day) for 3–6 months do not affect endometrial thickness or histology (Baber et al. 1999,
Duncan et al. 1999, Scambia et al. 2000, Upmalis et al. 2000, Balk et al. 2002, Penotti et al. 
2003), but the effects of isoflavonoids on expression of ER and PR in human endometrium 
had never been studied before. After the start of our trial it was reported that red clover-
derived isoflavones (50 mg/day) do not affect the expression of endometrial Ki-67 in 
perimenopausal women (Hale et al. 2001). We can now expand this knowledge to concern 
postmenopausal women, whose endometrium remained totally unaffected by isoflavonoid 
supplementation.  
Bone mineral density (not to mention incidence of fractures) takes years to show 
any changes in response to any treatment. Hence, various markers reflecting bone resorption 
and formation are most often used to assess the effects of a given compound on bone, and 
they respond to various treatments well in three to six months (Delmas 2000). Isoflavonoid 
treatment was found to reduce the output of bone resorption markers in our study. However, 
this response was not so marked as reported in some other trials involving genistein; 54 
mg/day was claimed to decrease Pyr output by 54% and Dpyr output by 55% in six months 
(Morabito et al. 2002). It has also been reported that whole soy foods containing isoflavones 
(60 mg/day) cause a fall of 14% in NTx levels in three months (Scheiber et al. 2001).
However, in some other trials, isoflavones (47–82 mg/day) have led to no changes in NTx 
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(Potter et al. 1998, Chiechi et al. 2002, Knudson Schult et al. 2003). These discrepancies may 
be explained by a number of factors, e.g. differences in study populations; genetic, life-style 
and environmental factors may well play a role in the response of bone to phytoestrogens. No 
effect of isoflavonoids on bone formation markers was seen in our study. The data are in line 
with some previous data (Alekel et al. 2000, Knudson Schult et al. 2003), but in contrast to 
some others (Wangen et al. 2000, Morabito et al. 2002, Atkinson et al. 2004). It is known that 
bone formation markers need exposure times longer than three months to exhibit significant 
changes, e.g. only after 6 months’ exposure to HT or bisphosphonates are significant changes 
detected (Delmas 2000), and thus the three-month duration of isoflavonoid use in our study 
was probably too short to affect bone formation to the extent that it could be seen in the 
markers assessed in our study. 
Lipids and lipoproteins are the most established surrogate markers of vascular 
risks (Greenland et al. 2003). It was initially thought that isoflavonoids present in soy could 
account for the lipid benefits (Clarkson 2002). This concept was challenged by data showing 
no effect of isolated isoflavonoids on circulating lipid concentrations (Nestel et al. 1997,
Hodgson et al. 1998, Simons et al. 2000, Dewell et al. 2002, Lichenstein et al. 2002). Our 
data concur with those studies; isoflavonoids had no effect on the serum levels of total 
cholesterol, LDL, HDL, or HDL-2 cholesterol, triglycerides, apolipoprotein A1, 
apolipoprotein B, or Lp(a). However, it has been shown that isoflavonoids (34–132 mg) can 
reduce LDL cholesterol levels (6–10%) if given in combination with soy protein (Washburn 
et al. 1999, Teede et al. 2001, Wangen et al. 2001, Dalais et al. 2003). Thus it seems possible 
that soy protein is needed for an effect of isoflavonoids on lipid levels. This has been 
supported by associations between falls in lipid levels and the amount of isoflavonoids with 
soy protein in some (Crouse et al. 1999, Merz-Demlow et al. 2000, Wangen et al. 2001) 
although not in all studies (Potter et al. 1998, Somekawa et al. 2001, Jenkins et al. 2002a). Of 
course we cannot exclude the possibility that more prolonged use of our regimen would have 
had a different effect, but in view of the previous data this seems unlikely. 
The isoflavonoid regimen failed to affect the levels of CRP, a recently 
discovered marker of CVD (Ridker et al. 2002). Thus, the isoflavonoids affected the synthesis 
of CRP neither in the liver nor in the vascular walls if it is indeed produced in a vascular 
lesion. This is in line with data of others (Jenkins et al. 2002b), which were published during 
our trial. It seems unlikely that isoflavonoids exert any vascular effects through CRP. We may 
also speculate that the consumption of isoflavonoids is not a confounding factor in 
epidemiological studies assessing the representativeness of CRP as a marker of CVD.  
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We assessed NO release by measuring plasma NOx, which shows great 
individual variation and is affected, among other things, by intake of dietary NOx; this source 
of error was eliminated as well as was possible in a clinical study. Isoflavonoids failed to 
affect plasma NOx levels, and this may reflect a real lack of effect of isoflavonoids on NO 
synthesis in our subjects, or insensitivity of the NOx assay to detect small changes in NO 
release, which could, however, be physiologically significant. Our data are in contrast with 
those of Squadrito et al. (2002), who reported that genistein (54 mg/day) for 6 months 
stimulated the release of NO and improved flow-mediated endothelium-dependent 
vasodilatation in healthy postmenopausal women. We acknowledge that assessment of 
vascular dilation in response to intra-arterial injection of acetylcholine may be an appropriate 
method, and by means of this method isoflavones have been shown to enhance NO release in 
female monkeys (Honoré et al. 1997) and in healthy middle-aged men and women (Walker et
al. 2001). Unfortunately, this time-consuming method was not available in our study. 
There are no previous data on the effects of isoflavonoids on E-selectin, which 
is also derived from the endothelium. In our study serum concentrations of E-selectin fell 
significantly (4.0%) during the isoflavonoid regimen, but also during the placebo regimen, 
although to a lesser degree. This difference, and the dependence of the reductions in E-
selectin concentrations on daidzein and genistein levels, may suggest that phytoestrogens can 
reduce the levels of E-selectin, at least at high concentrations. This reduction, if proved to be 
true in a larger study, is in theory vasoprotective (Blake and Ridker 2001). In this regard 
isoflavonoids may resemble HT regimens, which are known to reduce the levels of E-selectin 
by 18–35% (Cushman 1999, Farzati et al. 2002, Ylikorkala et al. 2003a).
Our study was among the first in which the effects of isolated isoflavonoids on 
glucose-insulin balance have been evaluated. The isoflavonoid regimen failed to affect this 
balance in our subjects, who were normoinsulinemic and of normal weight. This may appear 
to be in contrast to the fact that a soy-isoflavone combination may enhance insulin sensitivity 
in healthy postmenopausal women (Goodman-Gruen and Kritz-Silverstein 2001) and in 
women with type 2 diabetes (Jayagopal et al. 2002). This suggests that soy protein itself, or 
some other possible components in soy are important in the regulation of insulin sensitivity, 
which is inert to purified isoflavones, as we showed here. We also produced novel data on 
ghrelin during the isoflavonoid regimen, and although these data imply no effect or only a 
minor effect of isoflavones on this recently discovered regulator of insulin sensitivity, we 
acknowledge that much more data are needed before we can draw any definitive conclusion 
on the possible effect of isoflavonoids on ghrelin. 
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Summing up, isolated isoflavones (114 mg/day) for three months did not 
alleviate menopausal symptoms or improve quality of life; neither did it affect the vagina or 
endometrium. The isoflavonoid regimen slightly inhibited bone resorption, but had no effect 
on markers of bone formation or of vascular health. Although our findings on isolated 
isoflavonoids in the treatment of menopausal complaints were disappointing, it is worth 
emphasizing that isoflavonoids in combination with either soy products including soy protein 
or low dose estradiol may act differently. Thus, long-term prospective randomized trials on 
the ultimate usefulness and safety of isoflavonoids in such combinations in the treatment of 
menopause are needed. However, we conclude that our data give hardly any support to the 
widespread use of isoflavonoids alone for the treatment of menopause, as is commonly the 
case.
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CONCLUSIONS 
On the basis of the present work, the following conclusions can be drawn: 
1. Ingestion of isolated isoflavonoids (114 mg/day) for three months leads to consistent 
rises in the circulating levels of isoflavonoids. However, this regimen does not 
alleviate climacteric symptoms, or improve the quality of life. Neither does it affect 
weight, blood pressure, or circulating levels of FSH, LH, estradiol or SHBG.
2. The isoflavonoid regimen used had no effect on the vagina or endometrium.  
3. The isoflavonoid regimen slightly inhibits bone resorption, as seen from falls in the 
urinary output of pyridinoline (9%) and deoxypyridinoline (5%). Bone formation 
markers were not affected by this regimen.  
4. The isoflavonoid regimen did not affect the concentrations of total cholesterol, high- 
and low-density lipoprotein cholesterol, triglycerides, apolipoproteins B and A1, and 
lipoprotein (a), or the glucose-insulin balance. Levels of ghrelin were at a higher level 
during the isoflavonoid regimen than during use of the placebo. These data fail to 
support a vasoprotective role of phytoestrogens.
5. The isoflavonoid regimen did not affect the levels of either CRP or NOx, but the levels 
of E-selectin fell slightly. These findings also imply no effect or a minimal vascular 
benefit of isoflavonoids.
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